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Expanding the Repertoire of Chemical Modulators for Heat Shock Protein 70 
(Hsp70): New Probes for Neurodegenerative Disease  
by 
Christopher G. Evans 
Chair: Jason E. Gestwicki 
 Heat shock protein 70 (Hsp70) is a molecular chaperone that plays pivotal roles in 
protein homeostasis in nearly all organisms. In these roles, Hsp70 binds to newly 
synthesized or misfolded proteins and regulates their stability and turnover. Genetic and 
biochemical data have strongly implicated Hsp70 in many diseases, including cancer and 
neurodegeneration. However, there are few Hsp70 inhibitors available. This limitation 
has prevented detailed studies of Hsp70’s roles in disease and has limited exploration of 
its potential as a drug target. 
 The purpose of this study is to synthesize new chemical probes that could be used 
to aid in our understanding of Hsp70’s biology. Early Hsp70 inhibitors were assembled 
by the multi-component Biginelli reaction and they contained a dihydropyrimidine core. 
In my work, this reaction was further exploited to assemble a focused library of related 
compounds. This new series allowed for the identification of the putative binding site on 




formation. Based on this work, I generated a series of related dihydropyridines through 
the four-component, Hantzsch reaction. During the course of that work, an 
enantioselective route was developed using an organophosphorous catalyst. Some of 
these compounds showed promising activity in cellular models of neurodegeneration. 
Finally, derivatives of the natural product analog, 15-deoxyspergualin, were synthesized 
through the strategic use of the Ugi multi-component reaction. We found that this route 
provided for the rapid and efficient generation of derivatives, with increased 
opportunities for structural diversity. These compounds appeared to interrupt binding of 
Hsp70 to its co-chaperone, CHIP, and they blocked protein aggregation in cellular 
models. 
 Through utilizing different multi-component reactions, it has been possible to 
synthesize several new inhibitors of Hsp70. These probes have been used to better 
understand the relationships between Hsp70 and neurodegeneration. Thus, this series may 














1.1 Introduction to Hsp70 Structure and Function  
Heat shock protein 70 (Hsp70) is a molecular chaperone that is expressed in 
response to stress, such as elevated temperature. In this role, Hsp70 is believed to bind to 
its protein substrates and stabilize them against denaturation or aggregation until 
conditions improve.1 In addition to its functions during a stress response, Hsp70 has 
multiple responsibilities during normal growth; it assists in the folding of newly 
synthesized proteins,2, 3 the subcellular transport of proteins and vesicles,4 the formation 
and dissociation of complexes,5 and the degradation of unwanted proteins.6, 7 Thus, this 
chaperone broadly shapes protein homeostasis by controlling protein production, quality 
control and turnover during both normal and stress conditions.8 Consistent with these 
diverse activities, genetic and biochemical studies have implicated this chaperone in a 
range of diseases, including cancer, neurodegeneration, allograft rejection and infection. 
This review provides a brief review of Hsp70 structure and function and then explores 
some of the emerging opportunities (and challenges) for drug discovery. 
1.1.1 Hsp70 is Highly Conserved.      
Members of the Hsp70 family are ubiquitously expressed and highly conserved; 




50% identical to human Hsp70s.9 Eukaryotes often express multiple Hsp70 family 
members with major isoforms found in all the major cellular compartments: Hsp72 
(HSPA1A) and heat shock cognate 70 (Hsc70/HSPA8) in the cytosol and nucleus, BiP 
(Grp78/HSPA5) in the endoplasmic reticulum and mtHsp70 (Grp75/mortalin/HSPA9) in 
mitochondria. Some of the functions of the cytosolic isoforms, Hsc70 and Hsp72, are 
thought to be redundant, but the transcription of Hsp72 is highly responsive to stress and 
Hsc70 is constitutively expressed. In the ER and mitochondria, the individual Hsp70 
family members are thought to fulfill specific functions and have unique substrates, with 
BiP playing key roles in the folding and quality control of ER proteins and mtHsp70 
being involved in the import and export of proteins from the mitochondria. For the 
purposes of this review, we will often use Hsp70 as a generic term to encompass the 
shared properties of the family members. 
1.1.2 Domain Architecture of Hsp70.    
All members of the Hsp70 family have an N-terminal nucleotide binding domain 
(NBD) (~40 kDa) and a C-terminal substrate-binding domain (SBD) (~25 kDa) 
connected by a short interdomain linker (Figure 1-1 A).10 The NBD consists of two 
subdomains, I and II, which are further divided into regions a and b. The Ia and IIa 
subdomains interact with ATP through a nucleotide-binding cassette related to those of 
hexokinase, actin and glycerol kinase.11, 12 The SBD consists of a 10-kDa α-helix 
subdomain and a 15-kDa β-sandwich. Crystal structures suggest that substrate peptides 
are bound in an extended conformation between loops of the β-sandwich and that the α-
helix subdomain acts as a “lid”.13 The substrates of Hsp70 are thought to include both 




intermediates,3 and exposed regions of fully or partially folded proteins. For example, 
Hsp70 is known to interact with clathrin, components of the transcriptional activation 
complex, nuclear hormone receptors and many others.5, 14, 15 This diversity of substrates 
is allowed by the low sequence selectivity of the SBD, which binds to most peptides 
composed of non-polar amino acids.16  
1.1.3 ATPase Activity of Hsp70.    
Many of the functions of Hsp70 appear to revolve around crosstalk between 




ATP, with some reports of E. coli DnaK binding with a Kd of 1 nM.17 Through an inter-
domain, allosteric mechanism, ATP binding increases the on- and off-rate of peptide 
binding in the adjacent SBD. In turn, nucleotide hydrolysis to ADP closes the “lid” and 
enhances the affinity for substrate (Figure 1-1 B).18 Likewise, interactions between the 
SBD and its substrates increase the rate of ATP hydrolysis in the NBD, suggesting that 
communication between the two domains is two-way.18 The mechanisms of inter-domain 
communication have been studied extensively and appear to involve the conserved, 
hydrophobic linker.19, 20 Thus, from a drug discovery viewpoint, this allostery in Hsp70 
provides multiple opportunities for chemical intervention, including inhibition of ATP 
turnover, substrate binding or even blocking inter-domain allostery. 
1.1.4 Hsp70 Co-Chaperones.    
As isolated proteins, the ATP hydrolysis rates of Hsc70 and DnaK are extremely 
slow, 0.003 and 0.0003 s-1, respectively.17, 21 In vivo, this property provides the 
opportunity for regulation by co-chaperones, which associate with Hsp70s and control 
their nucleotide turnover. For example, the J proteins (or Hsp40s) are a large group of co-
chaperones that stimulate ATP hydrolysis (Figure 1-1 B).22 In the human genome, at least 
40 different J protein genes have been identified23 and each contains the conserved, ~70 
amino acid J domain required for binding and stimulation of Hsp70s.24 NMR, 
mutagenesis and crystallography studies indicate that at least one binding site of the J 
domain is on the NBD.25, 26 Protein-protein interactions between the J domain and the 
surface of the NBD trigger an allosteric “hotwire” through the Hsp70 that enhances ATP 
turnover by approximately 7-fold. Thus, in the presence of a J-protein, the release of 




co-chaperones, the nucleotide exchange factors (NEFs) catalyze ADP release. The major 
NEF families include, the GrpE-like family,28 BAG family proteins,29 HspBP130 and the 
atypical Hsp70 homologs (e.g. Hsp110).31 All of these NEFs appear to bind the NBD and 
favor ADP release, but each class uses a different structural mechanism to achieve this 
effect.32 Together, the J-domain proteins and NEFs regulate ATP cycling, and therefore 
substrate binding by the Hsp70s. In addition, some of the co-chaperones independently 
bind substrates and, through this activity, have the potential to influence substrate 
selection by the Hsp70 complex.33, 34 Thus, although these co-chaperones do not have 
enzymatic activity, they are important regulatory factors and they are required for the 
many chaperone functions of Hsp70.  
A final group of co-chaperones, the tetratricopeptide repeat (TPR)-containing 
proteins, bind to the EEVD sequence at the extreme C-terminus of Hsp72 and Hsc70. 
Interestingly, the evolutionarily unrelated molecular chaperone, Hsp90, also contains the 
EEVD motif, allowing it to interact with TPR domains. The TPR is characterized by a 
34-amino acid motif that forms an antiparallel α-helical hairpin.35 Most proteins that 
have TPR domains also have domains with additional activities and, thus, these co-
chaperones are thought to recruit unique capabilities to the Hsp70 complex. For example, 
HOP has three domains (TPR1, TPR2A, and TPR2B) with three TPR motifs each.36 HOP 
preferably binds to the ADP-bound form of Hsp70 family of proteins via TPR1 and 
TPR2B, while TPR2A specifically binds to Hsp90.37-39 In this way, Hop bridges Hsp70s 
and Hsp90, assists substrate transfer between these chaperones and is believed to promote 
substrate folding.40 Another TPR-domain protein, CHIP, contains a U-box domain and it 




and CHIP bind via TPR domains, the outcomes of these interactions are diametrically 
opposed: HOP favors folding, while CHIP favors degradation. Based on these 
observations and many others, it is thought that competition between co-chaperones 
might drive combinatorial assembly of chaperone complexes with specific functions.5, 8, 
43 Together, these features suggest that interfering with Hsp70’s interactions with co-
chaperones (e.g. J domains, NEFs and TPR domains) might be a viable mechanism for 
controlling chaperone function. 
1.2 Roles of Hsp70 in Disease 
1.2.1 Cancer and Apoptosis.    
Hsp70 expression has been routinely associated with poor prognosis in multiple 
forms of cancer.44 For example, high Hsp70 levels are associated with adverse outcomes 
in breast, endometrial, oral, colorectal, prostate cancers as well as certain leukemias.45-48 
Moreover, transgenic over-expression of Hsp70 is sufficient to induce T cell lymphoma 
in some models.47 This observation is important because induction of Hsp70 can be 
misregulated in cancer, potentially mediated by the heat shock transcription factor 1 
(HSF1).44, 49, 50 In cancer cells, over-expression of Hsp70 is thought to provide a survival 
advantage because it is able to interact with multiple components of both the caspase-
dependent and –independent apoptotic pathways (Figure 1-2 and Table 1-1).44, 51, 52 For 
example, this chaperone was reported to down-regulate the important apoptotic mediator, 
Bcl-2.53 Similarly, expression of Hsp72 blocks TNF-induced apoptosis, activation of 
caspase-3, translocation of Bax and cleavage of PPAR.54-57 Some of these interactions 
are thought to be direct. For example, immunoprecipitation has shown an interaction 




its oligomerization, a step necessary for disruption of the mitochondrial membrane.56, 57 
By influencing multiple steps in the same cascade, Hsp70 is likely to exert even more 
potent anti-apoptotic activity than if it was acting at individual proteins. Similarly, Hsp70 
has also been found to impact cell survival at multiple pathways by also blocking 
caspase-independent signaling through activity on cathepsins and Apaf-1.58 For example, 
Hsp70 knockdown increases cathepsin B release and protects lysosomes from photo- and 




and –independent apoptotic pathways, Hsp72 also plays roles in senescence through 
effects on the p53-p21 pathway.60 Together, these results suggest that Hsp70 proteins 
interacts with multiple partners in both the apoptosis and senescence pathways, a model 
that is consistent with Hsp70’s known substrate promiscuity. Importantly, the ATPase 
activity of Hsp70 doesn’t appear to be required for all of these activities, as the action of 
Hsp70 on JNK and AIF occurs independent of nucleotide hydrolysis.61-63 64 This is an 
important observation, because many of the early Hsp70 inhibitors target its ATPase 
activity. While shRNA-mediated knockdown of Hsp70 induces apoptosis and slows cell 
proliferation in multiple cancer cell models,46, 65, 66 it is unclear whether inhibitors of 
specific Hsp70 functions, such as nucleotide turnover, will mimic this cellular effect. 
Regardless, these studies suggest that cancer cells become “addicted” to Hsp70 through 




Hsp70 over-expression has also been documented to provide resistance to 
chemotherapeutic agents, such as imatinib, etoposide, cisplatin and MG-132.68, 69 
Although the detailed mechanisms of resistance remain to be elucidated, recent evidence 
suggests that reduced activation of ERK, NF-κB, and JNK pathways may be 
responsible.69 The protective effects of Hsp70 are particularly striking in response to 
treatment with Hsp90 inhibitors, such as geldanamycin and its derivatives.67, 70 Like 
Hsp70, Hsp90 is an ATP-utilizing molecular chaperone with roles in protein turnover.71 
However, Hsp90 is often considered the more “specialized” chaperone, with a relatively 
restricted set of cellular substrates. Hsp90’s substrates include Akt, Cdk4, Raf1, Her2 and 
other important anti-apoptotic targets, some of which appear to be shared with Hsp70 
(see Figure 1-2).71, 72 Inhibitors of Hsp90 lead to rapid, proteasomal degradation of these 
substrates and the promising anti-cancer potential of Hsp90 inhibitors has been reviewed 
extensively elsewhere.50, 73, 74 In the context of our discussion, treatment with Hsp90 
inhibitors has been found to induce expression of Hsp70, potentially through activation of 
HSF1.70 As discussed above, this compensatory mechanism can cause resistance to 
apoptosis and stabilization of some shared protein substrates.67, 70 Together, these 
observations suggest that dual therapy against both Hsp90 and Hsp70 might be 
beneficial. This hypothesis is strongly supported by observations that RNAi knockdown 
of Hsp70s enhances the efficacy of Hsp90 inhibitors.75, 76  
1.2.2 Protein Misfolding and Neurodegenerative Disease.     
One of the other important roles of Hsp70 is to assist protein folding and turnover. 
In normal cells, quality control systems prevent the accumulation of toxic misfolded 




misfolding can often occur.77-79 As post-mitotic cells, neurons appear to be particularly 
sensitive to these effects and, consistent with this idea, many neurodegenerative diseases 
involve aberrant protein accumulation. Genetic studies have routinely linked Hsp70 and 
its co-chaperones to this process and, thus, it has emerged as a potential drug target for 
multiple neurodegenerative conditions (Table 1-2). One recent example has shown that 
Hsp70 directly stabilizes lysozomes and plays a key role in Niemann-Pick disease.80 We 




Polyglutamine (polyQ) diseases are a family of at least nine inherited 
neurodegenerative disorders, including Huntington’s disease (HD), spinocerebellar ataxia 
(SCA), and spinal and bulbar muscular atrophy (SBMA), caused by the expansion of 




of an abnormally long glutamine tract in the synthesized protein.84 PolyQ expansion 
renders disease proteins prone to aggregation, and the extent of aggregation is correlated 
with the length of the polyQ.84 In vitro, Hsp70 family members (along with its J-domain 
co-chaperone Hdj1) can partially suppress the aggregation of the polyQ-expanded exon 1 
of huntingtin (htt) in an ATP-dependent remodeling process.85 Importantly, these 
chaperones are only active when added during the lag phase of the aggregation reaction, 
which suggests that Hsc70 and Hdj1 preferably act on early, prefibrillar states (Figure 1-
3).85 Similarly, in a yeast model, over-expression of the yeast Hsp70, Ssa1, decreases 
aggregation of htt and increases its SDS solubility86 and over-expression of either full 
length Hsc70 or its SBD in mouse N2A neuroblastoma cells mildly decreases htt 
aggregation.87 However, these relationships appear to be complex because, in O23, COS-
7, PC12, SH-SY5Y, and HEK293 cells, Hsp70 over-expression showed little effect on htt 
aggregation.88, 89 Similar themes are observed in animal models. For example, in fly 
models of SCA1 and mouse models of SCA1 and SBMA, Hsp70 family members 
suppresses the neurodegenerative phenotypes,90-92 while no significant effect is observed 
in mouse models of HD or SCA7.93, 94 It is worth noting that it is not clear whether 
polyQ aggregation is a good surrogate for toxicity. Moreover, it is not clear if Hsp70’s 
effects on cell viability are always mediated by direct effects on polyQ assembly or 
through more general buffering of pro-survival signaling,95, 96 as discussed above.  
Despite these uncertainties, it is interesting to note that several co-chaperones, 
including J-domain proteins, CHIP and BAG, have dramatic effects on polyQ aggregate 
formation, either on their own or in concert with Hsp70. For example, over-expression of 




J-domain co-chaperone, Sis1, splits large inclusions into smaller foci.86 The TPR-domain 
co-chaperone, CHIP, ubiquitinates htt and facilitates its degradation in a U-box 
dependent manner (Figure 1-3).97 The over-expression of CHIP significantly reduces 
neurodegenerative symptoms in animal models of SCA1, SCA3, SBMA, and HD. 
Similarly, CHIP -/- mice have exaggerated disease progression in models of HD and 
SCA3.98-101 The role of Hsp70 in CHIP-mediated protection remains to be established, 
but current models suggest multiple roles for the Hsp70-CHIP complex.97, 98 The 
observations that Hsp70 co-chaperones have effects on polyQ diseases suggest that the 
best protection against polyQ toxicity might require interplay between multiple 
components of the chaperone complex. Indeed, it has been shown that chemical 
stimulators of the heat shock response, such as geldanamycin, 17-(allylamino)-17-
demethoxy geldanamycin, geranylgeranylacetone, and celastrol, upregulate multiple 
chaperone components and reduce neurodegenerative symptoms in cell culture, fly, and 
mouse models of SCA1, HD, and SBMA.102-105  
Alzheimer’s disease (AD) is the most common neurodegenerative disease and its 
patients are characterized by progressive memory loss and accumulation of senile plaques 
(SP) composed of β-amyloid (Aβ) and neurofibrillary tangles (NFT) assembled from 
tau.106 Current models suggest that self-association of Aβ or tau into β-sheet rich 
oligomers leads to neuronal cell death (Figure 1-3).106, 107 Hsp70 family members have 
been shown to play important roles in the aggregation and cytotoxicity of both Aβ and 
tau. Hsp72 blocks the early stages of Aβ aggregation in vitro at substoichiometric levels 
(Figure 1-3), and Hsp70 has been shown to alter processing of the amyloid precursor 




caspase-9 and accelerating the elimination of Aβ.110 Tau directly binds to Hsp70 via two 
sites within its tubulin-binding repeats, which is the same region required for tau self-
association.111 This finding suggests that Hsc70 binding to tau might compete with self-
aggregation and toxicity111 and, consistent with this model, over-expression of Hsp70 
reduces aggregated tau in mouse models.112 Moreover, increasing Hsp70 levels promotes 
tau binding to microtubules and reduces the levels of hyperphosphorylated tau.113 Similar 
to the polyQ examples listed above, co-chaperones of Hsp70 also play roles in tau 
processing. For example, CHIP ubiquitinates phosphorylated tau in an Hsc70-dependent 
manner114, 115 and its over-expression accelerates tau degradation, reduces formation of 
insoluble tau and rescues tau-induced cell death (Figure 1-3).115, 116 The TPR-domain co-
chaperones, BAG-1 and BAG-2, also impact tau aggregation, but in opposing ways.117, 
118 An Hsc70-BAG-1 complex binds to tau and inhibits its turnover.117 In contrast, BAG-
2 and Hsc70 form a microtubule-tethered complex that can capture and deliver insoluble 
and phosphorylated tau to the proteasome for degradation (Figure 1-3), likely through a 
ubiquitin-independent mechanism.118 Together, these results illuminate the complex 
relationships between Hsp70, its co-chaperones and their impact on AD and other 
tauopathies.  
1.2.3 Infectious Disease and Immunity.    
The prokaryotic Hsp70, DnaK, is required for survival of bacteria under stressful 
conditions, such as thermal stress and challenge with heavy metals or antibiotics (Table 
1-3).119-121 Consistent with this model, Staphylococcus aureus dnaK mutants have 
reduced viability and are susceptible to stress.122 Most strikingly, these mutations 




Likewise, dnaK or dnaJ mutations in Escherichia coli make the cells susceptible to 
fluoroquinolones.123, 124 These chaperones are also necessary for Salmonella enterica to 
invade epithelial cells and for Listeria monocytogenes to survive in macrophages.125, 126 
Thus, Hsp70 family proteins and their co-chaperones appear to be potential drug targets 





In addition to its roles in bacterial physiology, Hsp70 is also important in host 
immunological responses and cell-cell interactions. For example, in mammalian cells 
infected with a virulent form of Salmonella choleraesuis, the levels of Hsp70 correlate 
with an increase in TNF-α induced cell death.127 In another example, Mycobacterium 
tuberculosis leverages its own Hsp70 to activate inflammatory signals via NF-κB 
activation.128 Hsc70 and other heat shock proteins also play important roles in IKK 
signaling, endocytic trafficking and possibly in antigen presentation, suggesting roles in 
activation and regulation of immune cells.129-131 
1.3 Chemical Targeting of Hsp70s 
Given these complex roles of Hsp70 in disease, it is not immediately apparent 
whether a good therapeutic strategy would be to stimulate, inhibit or otherwise re-direct 
the activity of this chaperone with chemical agents. For example, would stimulation of 
Hsp70’s ATPase activity protect from neurodegeneration? Would inhibition sensitize 
cancer cells to apoptosis? Moreover, should the ATPase activity of Hsp70 be the ideal 
target or is another function (e.g. protein folding, protein trafficking etc.) more 
appropriate? Given the promiscuity of Hsp70’s interactions with proteins, is it possible to 
influence the processing of individual substrates or will inhibitors have global effects? 
Although the answers to many of these important questions remain unknown, work over 
the last decade has provided first-generation, Hsp70-targeted compounds.132, 133 
Interestingly, these compounds belong to a broad range of structural classes and some 
have distinct, non-overlapping binding sites on the Hsp70 surface. These observations 
suggest that there are multiple ways to impact Hsp70’s functions, such as through 




substrates. Importantly, these early probes have also begun to reveal unexpected aspects 
of Hsp70’s biology. Thus, even if these compounds do not directly lead to approved 
drugs, they have started to define Hsp70’s roles in disease. In the following sections, we 
review the known chemical classes and briefly highlight the medicinal chemistry efforts 
and biological findings enabled by these probes. 
1.3.1 Spergualin-like Compounds.     
In 1981, Umezawa and colleagues reported the identification of a compound with 
antibiotic and anti-tumor activity from a Bacillus sp.134 They further characterized the 
active compound as the polyamine, (-)-spergualin 1 (Figure 1-4).135 Kondo and 
colleagues carried out the total synthesis of this compound in 14% overall yield.136 
However, the natural compound was found to have poor stability in vitro and in vivo, 
which led to the synthesis of analogues, including 15-deoxyspergualin (15-DSG; 2).137, 
138 In an aqueous environment at pH 7, removal of the labile 15-hydroxyl group was 
found to improve stability to 2 days.139 The route to 15-DSG and its derivatives involves 
formaldehyde-mediated cyclization of spermidine, followed by coupling of the free 
amine to an amino acid and installation of the ω-guanidino fatty acid.140 Thus, this 




L1210 leukemia cells, only the glycine (3) and L-serine (4) derivatives retained activity, 
whereas even conservative replacements with alanine or leucine abolished function.140 
Likewise, variations in the polyamine regions, such as the number of methyl groups or 
secondary amines, decreased efficacy.138 Taken together, these results suggest that the 
structure-activity profile of spergualin analogues is surprisingly narrow. 
Despite the improved stability of 15-DSG, this compound still retained relatively 
poor bioavailability.141 In an attempt to circumvent some of these shortcomings, a series 
of derivatives was developed in which the amides are inverted and this change was found 
to greatly improve the molecule’s stability and activity.139 Following from these efforts, 
the hydroxyglycine moiety was substituted with a carbamoyl group, producing the 
promising derivatives tresperimus 5 and LF 15-0195 6 (Figure 1-4). However, in this 
series, only minor methyl substitutions were tolerated in a few positions without a 
dramatic loss of activity.142 For example, an R methyl group appended near the terminus 
(6) was tolerated, while the opposite stereochemistry (7) had no apparent Hsp70 binding 
and 3-fold reduced immunosuppressive activity.143 Likewise, conservative replacement 
of this methyl with an ethyl (8) greatly reduced activity. Other portions of the molecule 
were equally sensitive to manipulation; for example, replacement of the guanidine with a 
pyridine reduced activity by approximately 4-fold.143 Taken together, the structure-
activity studies have revealed a surprisingly limited range of acceptable modifications. 
Using immobilized compound, 15-DSG and its derivatives were found to bind to 
several proteins, including Hsc70 and Hsp90.143 144, 145 Based on mass spectrometry and 
competition studies, it was further proposed that 15-DSG binds to the EEVD domain of 




of Hsp70’s functions, because 15-DSG was able to increase Hsc70’s ATPase rate by 
approximately 20 to 40%.148 Although this change in turnover rate seems minor, the 
biological activities of these compounds suggest that either (a) even modest changes 
might impact chaperone function or (b) ATP turnover is not the most relevant in vitro 
assay to describe their activity on the chaperone. More recently, 15-DSG was found to 
sequester Hsc70 in cells and limit its transport, which is proposed to stall protein 
synthesis.149 This effect could be reversed by the addition of EEVD peptide, consistent 
with its known binding site. Despite this evidence, other proteins, such as α1-
acidglycoprotein, have been suggested as targets of spergualin analogs.150 Based on these 
reports and the relatively modest affinity for Hsp70 and Hsp90, it seems likely that 15-
DSG and its derivatives may have multiple cellular targets.  
Although spergualin was first identified as an anti-infective and anti-tumor agent, 
15-DSG was subsequently identified as a potent immunosuppressant. The molecular 
mechanisms of this activity are not entirely clear, but 15-DSG has been proposed to block 
NF-κB trafficking and antigen presentation, two known cellular roles of Hsc70.131, 151 
Regardless, 15-DSG decreases the incidence of acute rejection in combination with 
cyclosporin and tacrolimus152 and it prolongs renal allograft survival.153 These 
immunological activities arise from 15-DSG’s effects on dendritic cells154 and 
leukocyte155 and monocyte151 activation; for example, Birck and colleagues looked at T-
cell activation in patients with Wegener’s granulomatosis and found that patients treated 
with 15-DSG had lower levels of proliferation markers, such as INF-γ and IL-10.153 
Similarly, treatment with 15-DSG leads to decreased mucosal injury and reduced TNF-α 




Based on these activities, 15-DSG has been explored in multiple clinical trials, 
with allograft rejection and malignant cancers being the most widely studied indications. 
For additional details an excellent review is available.150 Briefly, 15-DSG is poorly 
bioavailable (5%), so it is typically delivered by i.v. infusion.141 It displays a bi-
exponential decay, with an alpha half-life (t1/2) of 5 to 12 minutes and terminal half-life 
of approximately 2 hours.157 Metabolism is believed to occur, in part, through amine 
oxidases with seven inactive metabolites known.150 In rodents, infusion of 25 mg/kg/day 
for 9 days leads to a 4-6log reduction in tumor burden in a L1210 leukemia model.158 
However, a Phase I clinical trial of 15-DSG as a monotherapy against advanced 
malignancies showed no efficacy at 75 mg/kg/day.150 Similarly, a Phase II trial against 
metastatic breast cancer in 14 patients at 1800 or 2150 mg/m2/day by i.v. infusion for 5 
days also showed no efficacy. However, in both trials, 15-DSG was well tolerated and 
only low toxicity was observed (mild neuromuscular side effects as the only grade III 
toxicities).159 The experiences with immunological indications have been more 
promising. Since 1994, 15-DSG has been used in Japan for acute kidney allograft 
rejection.150 The advantage of 15-DSG is that, unlike FK506 or cyclosporin, it can be 
used up to 48 hrs after initiation of rejection and, therefore, can reverse ongoing rejection 
in animal models and humans. For example, 81% of patients undergoing acute renal 
allograft rejection in one study of 31 patients showed reversal of rejection with 
administration of 15-DSG, even as a monotherapy in some cases.160 Importantly, 15-
DSG is not a P450 substrate and it can be used with cyclosporin or steroids.157 In fact, 
studies of kidney and liver allograft rejections in Western Europe revealed 65% reversion 




clinical studies in Japan and the U.S. have been reported, and these generally document 
good tolerability, low toxicity and efficacy in transplant models.150 While 15-DSG has 
been used successfully in the clinic, the mechanism by which it exerts this effect is not 
fully understood. For example, how specific is this compound for Hsc70? If it is specific, 
how does binding to the EEVD control chaperone functions? Does the seemingly minor 
change in ATPase rate (20 to 40%) lead directly to the robust cellular effects? Is binding 
to both Hsp70 family members and Hsp90 important for activity? Clearly, additional 
structural and mechanistic experiments are needed. 
Given the promising biological activity of spergualin-like compounds, Brodsky 
and colleagues searched the Developmental Therapeutics database at the National Cancer 
Institute for related compounds. This effort yielded, NSC 630668-R/1 (R/1), which 
inhibits Hsc70’s ATPase activity and partially blocks chaperone-mediated protein 
translocation (Figure 1-4).162 However, unlike 15-DSG, R/1 inhibits stimulation of 
Hsc70’s ATPase activity by J-domain co-chaperones.162 This result is interesting 
because, although R/1 was originally identified as a 15-DSG analogue, it appears to 
operate by a different mechanism.  
1.3.2 Dihydropyrimidines.     
Following the successful identification of R/1, Brodsky and colleagues searched 
for other scaffolds able to alter Hsp70’s ATPase activity. Guided by structural similarity 
to 15-DSG and R/1, they focused on a series of functionalized dihydropyrimidines 
(Figure 1-5).163 The synthetic route to these compounds leveraged consecutive, Biginelli 
and Ugi multi-component reactions to yield diversity. In an ATPase assay, several 




while others enhanced this activity (e.g. MAL3-90 (10)).163 Moreover, the activity of 
these compounds was dependent on the presence of a J-domain co-chaperone, similar to 
what had been seen with R/1.162 For example, compound 9 had no effect on ATP 




added to the combination of Hsc70 and the J-domain of T-antigen.163 Approximately 30 
compounds were tested in these experiments and, accordingly, quantitative SAR was not 
readily apparent. To further explore this series, seventeen additional dihydropyrimidines 
were synthesized in which the Ugi-derived peptoid portion was replaced with a protease-
resistant, beta-peptide.164 The activity of these derivatives was tested against the ATPase 
activity of two Hsp70s (either Hsc70 or DnaK) in complex with a J-domain co-
chaperone. The results of that study suggest that hydrophobic substitutions near the 
dihydropyrimidine core (R4; Figure 1-5) may be important for activity. For example, 
compounds 11 and 12, which have phenyl substitutions in this region, changed ATP 
turnover by between 20 and 45%.164 Interestingly, 11 was an inhibitor of ATPase 
activity, while 12 was a stimulator, consistent with the general observations that 
compounds of this class can have either type of activity when J-domains are present. 
Also, 12 only stimulated bovine Hsc70 and not E. coli DnaK, suggesting that these highly 
homologous proteins might be independently targeted. Despite these efforts, the potency 
of these compounds is very weak (EC50 values ~ 75-300 µM), making it challenging to 
interpret the SAR and to confirm selectivity for Hsp70 in cells. Part of the challenge, 
until recently, was that compounds had to be tested in small numbers because a high 
throughput assay for Hsp70’s ATPase activity had not been available. To improve this 
capacity, Chang et al. converted a malachite green assay into a high-throughput platform 
for DnaK. Importantly, this assay employs purified DnaK and its co-chaperones, DnaJ, 
and GrpE, to boost the signal and provide physiological turnover rates.165 This advance 
allowed screening of a collection of more than 180 dihydropyrimidines and, from these 




DnaK’s activity at 150 µM, were identified. To complement this approach, a medium 
throughput luciferase-refolding assay was developed. In this assay, denatured firefly 
luciferase is diluted in the presence of the three-component chaperone complex and 
refolding is monitored by recovered luminescence. The ~180 member dihydropyrimidine 
collection was screened in 96-well format and the best of these compounds, such as 15, 
had EC50 values around 4 µM.166 Some compounds in this series inhibited chaperone-
mediated luciferase folding, while others were stimulatory. Interestingly, there was not 
obvious structural similarity between the active compounds from the ATPase assay and 
the luciferase-folding assay.  
Even though the dihydropyrimidines identified to date have relatively weak 
activity and their selectivity remains to be established, the first-generation compounds 
have been employed in a variety of biological systems. Importantly, these studies have 
provided surprising insights into Hsp70’s functions in disease models. In one example, 
the stimulatory dihydropyrimidine, 13, was found to enhance the Hsp70-mediated 
inhibition of amyloid-β aggregation.108 Conversely, a weak inhibitor of ATPase activity 
led to suppression, suggesting that the ATP hydrolysis rate of the chaperone might impact 
its anti-aggregation activity in vitro. To test this model in cells, Jinwal et al. used both 
inhibitors and activators of Hsp70’s ATPase activity in a model of tau aggregation.167 
Surprisingly, they found that stimulators, including 13, led to dramatic accumulation of 
tau by Western blot analysis, while inhibitors had the opposite effect. The inhibitors 
reduced tau levels via rapid ubiquitination with EC50 values of ~5 to 10 µM. Importantly, 
over-expression of Hsp70 promoted the activity of the inhibitors and lowered their EC50 




suggest that this result could be achieved by the inhibitors keeping the Hsp70 family 
member in a specific conformation, such ATP-bound, which is conducive to interactions 
with components of the ubiquitin-proteasome system (Figure 1-1 B). Thus, the net result 
of ATPase inhibitors appears to be ubiquitination of the bound protein substrate. Finally, 
intracranial injection was found to reduce tau in tau transgenic mice, which suggests that 
inhibiting the ATPase activity of Hsp70 might be a viable strategy for reducing the 
accumulation of misfolded tau. In addition to these studies on protein misfolding and 
aggregation, dihydropyrimidines have also been employed to explore the potential of 
Hsp70 as a target in apoptotic signaling and cancer. For example, compound 9 was found 
to have good anti-cancer activity against SKBr3 cells by decreasing cell viability.168 This 
activity appears to be mediated by the ability of the dihydropyrimidines to interrupt 
stimulation of Hsp70 by J-protein co-chaperones, because the GI50 values for a series of 
peptoid-modified dihydropyrimidines tend to correlate with their activity in a J-
stimulated ATPase assay.169 Moreover, the best compounds (of the nearly 50 derivatives 
tested) had promising GI50 values of approximately 6 to 10 µM against SKBR3 cells, 
suggesting the possibility that inhibition of Hsp70 alone is sufficient to induce apoptosis. 
To explore the potential mechanisms for anti-cancer activity, the effects of activators and 
inhibitors on stability of the pro-survival target, Akt, were explored.170 In that study, it 
was found that activators promote Akt stabilization, while inhibitors promote dramatic 
Akt degradation and subsequent cell death in a panel of cancer cells.170 This mechanism 
is similar to that proposed for Hsp90 inhibitors, which involves selective destabilization 
of key survival substrates, including Akt.72 Because Hsp90 and Hsp70 often cooperate, it 




Together, these studies suggest that inhibition of Hsp70’s ATPase activity leads to 
degradation of key apoptosis substrates in cancer cells. Further work is needed to 
understand the molecular mechanisms; however, these collective findings, across 
multiple models of protein misfolding and apoptosis, have begun to reveal potential 
avenues towards therapeutic intervention. 
1.3.3 Fatty Acids.     
Sulfogalactosyl ceramide and sulfogalactoglycerolipid are two sulfoglycolipids 
that have been found to bind Hsp70. Mamelak and Lingwood identified their putative 
binding site on the NBD through deletional analysis and site-directed mutagenesis; 
specifically, mutation of two residues in the NBD (Arg 342 and Phe 198) led to reduced 
binding of 3’sulfogalactolipid.171 It was further shown that the aglycone portion 
determines whether the molecules bind to bacterial or eukaryotic Hsp70s. Eukaryotic 
Hsp70 bound SG24Cer, SG18Cer, and SG20:OHCer while DnaK preferentially bound to 
SG18:1Cer and SG20:OHCer.172 Other substitutions on the aglycone or manipulations of the 
sulfation (or phosphorylation) pattern on the sugar ablated binding, demonstrating the 
narrow tolerance in these regions.173 A full SAR analysis of this class of molecules 
awaits expanded library synthesis and additional structural studies. However, early 




affinity for Hsp70 (Figure 1-6). Compound adaSGC (16) was found to have an IC50 value 
of ~50 µM.171 Interestingly, adaSGC is a noncompetitive inhibitor of ATPase activity, 
but the molecular mechanism of inhibition is not entirely clear.174 In cells, 16 increases 
the protein levels of ΔF508CFTR,174 a mutant of the cystic fibrosis transmembrane 
receptor (CFTR) that is prone to misfolding and degradation through ER-associated 
degradation (ERAD). Thus, this finding suggests that inhibition of Hsp70’s ATPase 
activity might suppress the ERAD pathway that normally acts to reduce the levels of 
mutated CFTR, a result that would have implications on cystic fibrosis and other 
misfolding diseases. Moreover, the activity of 16 was found to be dependent on the 
actions of both Hsp70 and a J-domain containing co-chaperone, consistent with this 
complex as a cellular target. Despite these insights, the binding site for these glycolipids 
is only loosely defined and, further, their selectivity has yet to be firmly established. 
Another example of a fatty acid-like derivative that inhibits Hsp70 function is the 
acyl benzamide family. This class of compounds arose from work by the Schiene-Fisher 
group in which they targeted the cis/trans aminopeptidyl isomerase (APIase) activity of 
DnaK, in an effort to identify potential antibiotics. DnaK has been shown to catalyze 
isomerase activity through a poorly understood mechanism. Efforts to target this activity 
with small molecules yielded acyl benzamides with IC50 values as low as 2.7 µM.175 
Further, they found that the length of the fatty acid chain is an important determinant of 
the molecule’s activity (Figure 1-7). For example, short acyl chains, such as those in 17, 
gave compounds with poor activity in both APIase and bacterial growth assays. 
Increasing the length of the chain tended to enhance potency: compound 18 had an IC50 




IC50 of 1.2 µM and MIC of 180 µg/mL. However, increasing the fatty acid chain-length 
also enhanced undesirable erythrocyte hemolytic activity. Hemolytic activity could be 
partially avoided by installation of unsaturations in the fatty acid; for example, compound 
20, with a cis alkene at C9, had an EC50 >1500 µg/mL in the hemolytic assay, while it 
retained activity against APIase (36 µM) and bacterial growth (280 µg/mL). Substitutions 
in the amino acid portion (R1) altered the MIC values, with less predictable effects in the 
other in vitro assays.175 For example, dramatic substitutions of the isoleucine for a 
glutamine (21) or phenylalanine (22) caused modest changes in APIase inhibition but 
they increased the MIC by approximately 3- to 7-fold. Together, these findings suggest 
that the in vitro activity assays ascribed to Hsp70 might not best reflect the key 
mechanistic roles played by this chaperone in bacteria. This is a re-occurring theme in the 
Hsp70 field because the roles of measurable Hsp70 functions (e.g. ATPase, APIase, 
refolding) in controlling its biology in vivo remain uncertain. Despite this discrepancy, 




ampicillin, which suggests that these compounds or their derivatives may be useful. 
However, it is important to note that their selectivity for Hsp70 has not been formally 
established and any off-target effects of these compounds remain unexplored. 
1.3.4 Peptides.     
As mentioned above, DnaK is considered a potential target for anti-bacterials, but 
this model has only recently been tested with pharmacological agents. For example, a 
series of 18-20 amino acid, proline-rich peptides, including drosocin, pyrrhocoricin, and 
apidaecin (Table 1-4), were described that bind DnaK (and another prokaryotic 
chaperone, GroEL) and kill susceptible bacteria without impacting mammalian cells.176 
Pyrrhocoricin inhibits the ATPase activity of E. coli DnaK and it binds in the SBD with a 
Kd of 50 µM.177 This interaction is thought to keep the “lid” domain in the closed 
position, preventing substrate release, a model supported by computational simulations 
and mutagenesis studies, which identified the SBD residues Glu589, Gln595, and Met598 
as the key targets in DnaK.178 Interestingly, pyrrhocoricin does not bind to S. aureus 
DnaK,177 suggesting a potential difference between gram-positive and –negative strains. 
In an effort to optimize the pharmacokinetics and antibacterial activity of these peptides, 
several analogues representing combinations of the consensus sequences were generated. 
Of these derivatives, GRPDKPRPYLPRPRPPRPVRL is the most active and it also has 




and a resistant strain of Enterobactericeae sp., with an MIC approximately 4 times better 
than ciprofloxacin. Moreover, it was not toxic to eukaryotic cells at concentrations up to 
1.5 mg/mL.179 Cudic et al. recently generated dimers of pyrrhocoricin in an effort to 
further improve stability and potency. Some of these compounds have increased serum 
stability compared to pyrrhocoricin and activity against isolates normally resistant to β-
lactams, tetracycline, or aminoglycosides.180 While these compounds have not advanced 
to the clinic, they have shown that targeting DnaK may be a viable anti-bacterial strategy 
and further work will likely improve stability and potency. 
1.3.5 ATP Mimics.   
Given that Hsp70’s ATPase activity appears to be one central determinant of 
chaperone function, compounds that are competitive for binding to ATP might be 
expected to have potent activity. This hypothesis arises, in part, from analogy with 
Hsp90, in which ATP competitive compounds, such as geldanamycin derivatives, induce 
degradation of Hsp90 substrates. Recently, Williamson et al. published the first 
adenosine analogues that can be used to test this important hypothesis in Hsp70. Using a 
fluorescence polarization assay, they screened adenosine derivatives and identified 8-
amino adenosines with affinity for the ATP-binding site, with the most active (23) having 
an IC50 of 4.9 μM (Figure 1-7).181 The intended binding orientation was confirmed by a 
co-crystal structure. Further, when the 8-amino group was substituted with 3,4-
dichlorobenzyl (24), it retained activity (IC50 ~ 9.1 µM) and had an improved toxicity 
profile. Subsequent modifications optimized the π-stacking with residues in Hsc70 and 
the 5-substituent (R2) was further substituted with a 4-cyanophenyl group to yield a tight 




HCT 116 colon carcinoma cells (GI50 of 5 μM) and it reduced the levels of Her2, a 
substrate that is sensitive to Hsp70 knockdown.181 Most recently, compounds from this 
class were also found to have synergy with an Hsp90 inhibitor in HCT116 cells,182 which 
might be expected based on shared functions of these chaperones. Together, these studies 
represent an important step towards submicromolar affinities and structure-guided design 
of Hsp70 inhibitors. 
1.3.6 Phenylethynesulfonamide.      
Recently, Leu and colleagues reported the identification of 2-
phenylethynesulfonamide (PES; 26) as a compound that binds Hsp72.183 PES (also 
known as Pfithrin-µ) has been shown to be selectively toxic to cancer cell lines and it was 
proposed to affect p53, but its mechanism of action had not been clear. Biotin-conjugated 
PES revealed Hsp72 (but not Hsc70, BiP or Hsp90) as a target and deletional analysis 
further restricted the binding site to the C-terminus.183 Using immunoprecipitations, the 
authors characterized the effects of PES on assembly of the Hsp70 chaperone complex in 
different cell lines. They hypothesized that PES would alter co-chaperone associations 
with Hsp72 and, thereby, alter chaperone functions. These studies revealed that PES 
prevents the interaction between Hsp72 and some BAG proteins, depending on the cell 
type. Moreover, PES blocks association of Hsp72 with p53, consistent with the ability of 
PES to kill cancer cells and block caspase activation. Finally, PES appears to interrupt the 
interaction of Hsp72 and LAMP2, an important protein in chaperone-mediated 
autophagy. Consistent with this idea, long-lived proteins are degraded at a reduced rate in 
response to PES and this compound causes build up of procathespin L, indicating that 




suggest that PES changes the interactions of Hsp70 with some of its co-chaperone 
partners and, through this activity, impacts substrate fate. Moreover, PES has a relatively 
simple structure and it seems likely that additional synthetic studies might improve its 
activity and, potentially, its selectivity. Those efforts will likely benefit from improved 
structural analysis and further biophysical studies on the mechanism for changes in 
Hsp70 complex assembly. 
1.3.7 Thiophene-2-carboxamides.    
Celliti et al. recently used NMR spectroscopy to identify compounds that bind to 
DnaK.184 They specifically explored the protons in the aliphatic region of the 1D 1H 
NMR spectra of E. coli DnaK SBD (residues 393-507) in an effort to find scaffolds that 
interact with that domain. These efforts yielded a pocket near Leu484 and Pro419, which 
forms a groove important for allosteric communication between the SBD and the NBD. 
The compounds that bound this site were principally thiophene-2-carboxamides, such as 
26, and their binding was confirmed by isothermal titration calorimetry (ITC), with Kd 
values around 70 µM. Based on these results, 15 derivatives with either a thiophene or 
furan core and a variety of hydrophobic groups appended to the 2-position were 
synthesized (Figure 1-7). Adding bulk to the R2 substituent seemed to improve affinity 
and these efforts yielded the indole-substituted 27, which bound with a Kd of 12.7 µM. 
Finally, members of this series of compounds were found to inhibit growth of E. coli and 
Yersinia pseudotuberculosis, with MIC values of approximately 10 to 400 µM depending 
on the strain and growth temperature. The best compound was the 2-substituted furan 28, 
which had an MIC of less than 12 µM against Y. pseudotuberculosis at 40 °C. 




the highest affinity to DnaK as determined by ITC, again suggesting a complex 
relationship between Hsp70 binding and in vivo potency. 
1.3.8 Other Scaffolds.    
Included in a comprehensive list of compounds with activity on Hsp70 are several 
molecules that have either recently been discovered or older ones that await further study. 
For instance, the rhodacyanine, MKT-077 (Figure 1-8), has been reported to bind to 
mtHsp70 for about a decade.185 Because of its cationic character, this compound is 
thought to accumulate across the mitochondrial proton gradient in rapidly dividing cancer 
cells. In that subcellular compartment, it is proposed to bind the ATP binding site of 
mtHsp70, leading to mitochondrial disruption and anti-cancer activity.186 In early 
experiments, MKT-077 was found to inhibit proliferation of multiple human cancer cell 
lines, including colon, bladder and breast carcinoma cells, with IC50 values ranging from 
1 to 5 µM with no toxicity against normal kidney cells.187 Based on these findings, pre-
clinical evaluation in rats revealed low toxicity below 3 mg/kg/day and primarily renal 
impairment above that dose. In mouse xenograft studies, continuous infusion was 
required for anti-tumor activity.188 Based on the preclinical findings, a Phase I clinical 
trial against solid tumors was performed using daily infusions carried out five times over 
three weeks at 30-50 mg/m2/day.189 In a subset of these patients, renal toxicity was again 
seen as the major toxicity. Importantly, pharmacokinetic measurements failed to detect 
MKT-077 above one micromolar in the serum, suggesting that therapeutic dose was not 
achieved. Consistent with this, little improvement in disease was seen (1 out of 10 
patients achieved stable disease).189 However, these studies suggest that targeting 




this scaffold could be improved. In addition, more detail about the selectivity and 
mtHsp70-binding activity of this compound might guide these efforts. 
Other interesting scaffolds include, tubocapsenolide A, a steroid-like molecule, 
which was identified as an inhibitor of Hsp70. It was proposed to oxidize thiols on both 
Hsp70 and Hsp90, causing their inactivation.190 Also, there are several reports suggesting 
that (-)-epigallocatechin gallate can inhibit Hsp70s, including BiP, allowing initiation of 
apoptotic pathways.191-193 Likewise, the flavonoid, myricetin, inhibits the ATPase 
activity of Hsp70s, reduces tau levels and has anti-cancer activity in multiple models.167, 
170 It should be clearly noted that polyphenols, such as epigallocatechin gallate and 
myricetin, are notoriously promiscuous. However, uncovering their binding site(s) and 
mechanism(s) on Hsp70 might reveal new “druggable” sites and opportunities for 
structure-guided design. Recently, an imidazole was reported by Williams et al. to induce 
apoptosis through interactions with Hsp70 and Hsc70194 and Haney et al. reported that 




the SBD.195 Finally, peptides derived from BAG1 were shown to inhibit the BAG1-
Hsc70 interaction and inhibit proliferation of breast cancer cells.196 These last results 
further emphasize the important contribution of co-chaperones in guiding the activity of 
the Hsp70 complex. While much work remains to optimize these compounds and 
establish their selectivity for Hsp70, they provide an illustration of the wide diversity of 
structures found to interact with this chaperone.  
1.4 Analysis and Prospectus 
Hsp70 is a critical molecular chaperone in cell survival signaling and protein 
homeostasis. As such, it has gathered significant attention as a potential, emerging drug 
target.44, 67, 132, 133 Genetic studies (e.g. knockdown and over-expression) have clearly 
demonstrate that Hsp70 and its co-chaperones are involved in cancer, neurodegeneration 
and other diseases. The next steps are to determine if the various functions of Hsp70 can 
be pharmacologically manipulated and, further, whether the outcomes of this intervention 
will be well tolerated. On first glance, targeting of a core mediator of protein homeostasis 
might be considered challenging, given its widespread cellular roles and ample 
opportunities for toxicity. In part, enthusiasm for Hsp70 as a drug target is based on the 
success of programs targeting other core molecular chaperones, such as Hsp90.67 As 
mentioned above, Hsp90 inhibitors specifically destabilize pro-survival signaling proteins 
in cancer cells and the results of early anti-cancer trials appear promising. However, the 
field of Hsp70 inhibitors is less mature and many, important questions remain before 
Hsp70 can be considered an equally good drug target.  
In this review, we have discussed some of the early efforts to identify inhibitors of 




However, many questions remain before Hsp70 can be considered a fully validated drug 
target. For example, there are multiple assays used to measure Hsp70 activity in vitro 
(e.g. ATPase activity, APIase activity, substrate folding, anti-apoptotic signaling, etc) and 
the relationships between any of these measurable functions and the chaperone roles of 
Hsp70 in vivo remain unclear. Additionally, there is a general lack of selectivity 
information for the first-generation, Hsp70-targeted compounds. Thus, it seems likely 
that at least some of these compounds are enacting their cellular activities through 
multiple pathways, which precludes definitive statements on Hsp70 as a drug target.  
Clearly, one of the major problems in the field is that consensus assays for 
studying Hsp70 are lacking. By analogy, Hsp90 inhibitors are often tested against a 
battery of standard assays, including those that measure chaperone binding in vitro and 
the ability to reduce the levels of Hsp90 substrates, such as Akt, Cdk4, Raf and Her2, in 
cells.74 Future efforts on Hsp70 will benefit from similar, routine utilization of (a) in vitro 
binding assays, (b) examination of cellular effects on putative Hsp70 substrates, such as 
tau, and (c) studying the effects of Hsp70 over-expression on compound efficacy. This 
last point is particularly important because, in our opinion, the interpretation of pull-down 
studies (which are often used to document Hsp70 binding in cells) are complicated by 
both the hydrophobic promiscuity of this chaperone and its abundance. Thus, over-
expression studies may provide a more readily interpretable alternative. Another 
interesting approach is transcriptional profiling, which was previously used to identify a 
novel Hsp90 inhibitor.197 Finally, a greater emphasis on structural studies seems 
warranted, to permit insights into the binding sites of putative Hsp70 inhibitors. In the 




into the binding sites. As the field of Hsp70 inhibitors matures, increasing utilization of 
structural analysis and broader assay profiling will ultimately accelerate discovery. 
It is interesting to note that a wide variety of chemical scaffolds (e.g. polyamines, 
fatty acids, sulfoglycolipids, peptides, nucleosides, etc.) have been identified with affinity 
for Hsp70. Although some of these scaffolds are likely promiscuous, this observation still 
suggests that Hsp70 harbors an unusual number of potential drug-binding sites that can 
accommodate a variety of chemical scaffolds. These sites might include deep pockets, 
such as those found in the ATP-binding cleft and substrate-binding region, and more 
shallow surfaces, such as those involved in allostery and protein-protein interactions with 
co-chaperones. Although not all of the compounds discussed herein have been explored 
in sufficient molecular detail, the early findings suggest that there are multiple ways to 
impact Hsp70’s functions. For example, PES, BAG1-related peptides and 
dihydropyrimidines seem to interrupt Hsp70’s contacts with co-chaperones, while 25 
directly competes for nucleotide binding. However, the suitability of each binding site for 
further development remains uncertain in most cases because direct relationships between 
the binding event and chaperone functions in vivo are not known. 
One interesting aspect of Hsp70 biology that remains to be more fully leveraged 
is the ability of this chaperone to form multi-protein complexes. As discussed above, 
Hsp70 interacts with multiple classes of co-chaperones and these partners are known to 
shape its activities. Thus, specifically targeting the interactions between Hsp70 and its 
regulatory partners would be expected to control chaperone activity. This approach might 
be expected to have reduced toxicity because it might reduce global impairment of 




complexes is not currently known.8 Thus, one cannot readily choose the right Hsp70 / co-
chaperone pair to target. Moving forward, we propose that an emphasis on the structural 
biology of co-chaperones, combined with a deeper insight into how these factors shape 
the proteome, will be required to rationally leverage Hsp70 as an effective drug target. 
In summary, genetic and biochemical studies support Hsp70 as an interesting, 
potential drug target in a remarkably wide range of diseases. Early studies on Hsp70 
inhibitors support this general conclusion. However, the field of Hsp70 inhibitors is 
clearly in its infancy and extensive work remains before it is clear how this chaperone 
can be best exploited. 
The goal of my thesis work, described in the following Chapters, is to explore the 
use multicomponent reactions to generate libraries of compounds that target Hsp70 
family members. My hypothesis is that multicomponent reactions might be a particularly 
powerful way to overcome the major challenges in the field. In Chapter 2, I use the 
Biginelli reaction to generate dihydropyrimidines that control ATP turnover by Hsp70. In 
Chapter 3, I focus on the Hantzsch reaction to approach this goal and develop the first 
enantio-selective, four-component route to dihydropyridines. In Chapter 4, I describe my 
work on the Ugi reaction to create analogs of the Hsp70-targeting compound, spergualin. 
The ultimate goal of this work is to identify compounds that can be used to understand 
how chaperones (i.e. Hsp70 proteins) are involved in neurodegenerative diseases. 
Notes 
This work has been published as “Heat Shock Protein 70 (Hsp70) as an Emerging Drug 
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Alzheimer’s disease (AD) is a neurological disorder that is characterized by the 
accumulation of plaques composed of aggregated amyloid beta (Aβ) peptide and 
neurofibrillary tangles composed of microtubule-binding protein tau. These structures are 
assembled by the ordered self-association of the component peptides, producing small 
soluble aggregates, intermediate oligomers and, eventually, the mature fibrils that deposit 
in the AD brain. As discussed in Chapter 1, over-expression of Hsp90, Hsp70 proteins 
and certain co-chaperones have been found to reduce AD-related pathology in models of 
AD. However, little is known about how Hsp70 might physically interact with these 
amyloid-forming proteins, which proteins are bound to the amyloid-forming protein and 
how this interaction might alter the course of disease. To better understand this 
relationship, we undertook a systematic analysis of how purified molecular chaperones 
impact Aβ aggregation in vitro. We found that Hsp70, in combination with Hsp40 and 
ATP, could specifically block formation of the pre-fibrillar Aβ structures. Interestingly, 
these chaperones were not able to reverse fibril formation. Finally, we used new chemical 
probes and hydrolysis-resistant nucleotide mimetics to demonstrate a key role for ATP 




2.1.1 Amyloid diseases 
The amyloid diseases are a collection of protein misfolding disorders associated 
with the formation of distinctive fibrils.1-5 Alzheimer’s disease is one of the most 
common amyloid diseases and it is characterized by fibrils composed of Aβ, a 39-43 
amino acid proteolytic fragment of the amyloid precursor protein (APP).6 Upon release 
from APP, Aβ becomes enriched in β-sheet structure and acquires the propensity to self-
assemble.7 Initial theories to explain the pathology of AD focused on the involvement of 
the visually striking fibrils, but more recent evidence has strongly supported a role for 
soluble oligomers.3, 8-10 Aβ oligomers can be prepared in vitro11, 12, biosynthesized by 
cultured cells13, 14, or collected from AD tissues15 and, in all cases, these structures are 
highly neurotoxic. Despite these important observations, numerous questions about the 
basis of disease are unanswered. For example, although there is active research in this 
area8, 11, 16, the number of Aβ monomers present in an oligomer hasn’t been fully 
described. Moreover, the subcellular site(s) of oligomer production and the conditions 
that lead to their assembly is still debated; fibrils are found in extracellular space but 
there is growing evidence that oligomers may be produced in intracellular 
compartments.8, 13, 17-19  Additional insights into the molecular mechanisms that 
contribute to AD are needed.  
One of the important consequences of the oligomer hypothesis is that it implies 
that therapeutic benefits could arise from preventing early (i.e. pre-oligomeric) stages of 
amyloid formation. Accordingly, small molecules that directly block Aβ aggregation20-22, 
reduce its production from APP23-25, decrease soluble amyloid load26, 27 and enhance 




approaches is to intervene at a stage prior to oligomerization and prevent accumulation. 
Consistent with this idea, it has been suggested that stimulating natural cellular 
mechanisms that combat protein aggregation, including proteases that digest Aβ and 
chaperones that inhibit misfolding, might have therapeutic benefit.31-33  
2.1.2 Genetic evidence for the role of chaperones in Alzheimer’s disease 
 Molecular chaperones are involved in many important aspects of protein 
homeostasis, including folding, degradation and subcellular trafficking.34-36 These tasks 
typically involve the heat shock proteins, such as Hsp70 and Hsp90, which (as discussed 
in Chapter 1) are chaperones that recognize misfolded polypeptides and use energy-
driven cycles of substrate binding and release to favor productive folding.37, 38 One of the 
important consequences of chaperone binding is that deleterious protein aggregation is 
prevented. Consistent with this activity, numerous studies have suggested that heat shock 
proteins are important for the prevention of amyloid formation.39-41,31, 42, 43  For example, 
genetic overexpression of Hsp70 has been shown to reduce amyloid-related phenotypes 
in mouse models of spinocerebellar ataxia type 144 and Parkinson’s disease45. Similar 
results are seen in Drosophila melanogaster46, Saccharomyces cerevisae47, 48, and 
Caenorhabditis elegans49 models of neurodegeneration. These experiments suggest that 
chaperones, particularly Hsp70, may bind amyloidogenic peptides and help prevent 
disease by restoring the balance between aggregation and folding. This hypothesis is 
supported by biochemical evidence in some systems. In models of AD, overexpression of 
molecular chaperones, specifically heat shock protein 70 (Hsp70) family of proteins, 
suppresses phenotypes related to Aβ aggregation. These observations led to the 




2.1.3 Hsp70’s involvement in the aggregation of amyloid beta 
Purified Hsp70 proteins blocks aggregation of α-synuclein, a protein implicated in 
Parkinson’s disease, in vitro.50  Similarly, addition of Hsp70 and its co-chaperone partner, 
Hsp40, to huntingtin, an aggregation-prone protein that causes Huntington’s disease, 
blocks oligomer formation.43, 51 In addition to these findings, other chaperones, such as 
Hsp2052 and Hsp10453, have been shown to limit amyloid formation in vitro. Together, 
the combination of genetic and biochemical evidence provides compelling support for a 
direct role of chaperones in these diseases. In Alzheimer’s disease, genetic evidence to 
suggest a role for chaperones has been reported54, but corresponding biochemical analysis 
is lacking. Similar to what occurs in other disease models, Hsp70 protein family 
overexpression improves the viability of cells that express excess Aβ.54 Additionally, 
abundant chaperone levels block formation of Aβ aggregates in C. elegans.49 
Biochemical evidence would help elucidate the mechanism(s) responsible for these 
favorable effects. For example, the type of Aβ structure (e.g. monomers, oligomers 
and/or fibrils) bound by chaperone is not known. Moreover, it isn’t clear how much 
chaperone is required or if this process is ATP-driven. A more detailed understanding of 
this system would be beneficial in both (a) understanding chaperone function and (b) 




2.1.4 Synthesis of Hsp70 modulators by the Biginelli reaction 
 As discussed in Chapter 1, early Hsp70 modulators, such as MAL3-101, were 
generated by the Bignelli reaction. For these compounds the Biginelli-derived 
dihydropyrimidines were subsequently subjected to the Ugi reaction to yield the final 
active compound.55 The Biginelli portion of the sequence of reaction employs three 
components. An aldehyde, urea, and β-keto ester are combined to form a 
dihydropyrimidine under conditions catalyzed by a Lewis or Brønsted acid. The most 
recent mechanism for this reaction was proposed by Kappe in 1997 (Scheme 2-1).56  The 
dihydropyrimidine scaffold has yielded a multitude of biologically active compounds 
some of which have been shown to have activity on Hsp70.57-62  Using these studies as a 
guide, we sought to generate Hsp70-targeted probes using this multi-component reaction. 
In turn, these reagents could be used to understand the relationships between Hsp70 and 





2.2.1 Recombinant Hsp70/40 blocks aggregation of freshly prepared amyloid beta 
(1-42)  
 
Results from overexpression experiments have suggested a role for Hsp70 family 
of proteins in the aggregation of amyloid beta54, but evidence for this interaction in vitro 
is lacking. To explore this question, freshly prepared amyloid beta (1-42) was treated 
with recombinant Hsp70 and its co-chaperone Hsp40 in the presence of excess ATP. 
Hsp40 stimulates Hsp70’s ATPase activity63, 64 at a low molar ratio (100:1 Hsp70:40). 
Thus, the goal of these experiments was to establish if an activated Hsp70/40 
combination could inhibit amyloid formation. In our initial experiments, we monitored 
turbidity to discern the extent of Aβ self-assembly.7  Strikingly, the results of these 
experiments revealed that Hsp70/40 is a potent sub-stoichiometric inhibitor (Figure 2-
1A). At a molar ratio of ~1:50 (overall chaperone:Aβ), Hsp70/40 significantly slowed the 
rate of aggregation and delayed the onset time. This effect was dependent on chaperone 
concentration; lowering the levels to less than ~ 1:200 abolished inhibition. To confirm 
these results under different conditions, we employed the well-known thioflavin T assay. 
Thioflavin T is an indicator dye that becomes strongly fluorescent in the presence of 
amyloid.65 Confirming the turbidity results, there was a strong dose-dependent decrease 
in fluorescence after 80 minutes of treatment with chaperones (Figure 2-1B). Finally, we 
used transmission electron microscopy (TEM) to examine the ultrastructure of the 
chaperone-treated samples. These experiments revealed that, rather than forming fibrils, 
Aβ was redirected into roughly circular structures by Hsp70/40 (Figure 2-1C). Although 





 that some Aβ escapes the block. Further, the barrier to aggregation wasn’t complete; 





2.2.2 The combination of Hsp70/40 is more effective than Hsp70 alone 
Hsp40 is a known co-chaperone and stimulator of Hsp70’s ATPase activity.66  
Thus, we were interested in understanding if the combination of Hsp70/40 is more 
effective than Hsp70 alone. This result would suggest that ATPase activity is important 
for Hsp70’s anti-aggregation function. To test this idea, we treated Aβ with Hsp70 or the 
combination (100:1 Hsp70:40) and monitored aggregation by the thioflavin T assay. 
Consistent with reports in other systems50, Hsp70 alone blocks aggregation (Figure 2-2). 




the chaperone alone. As a control, we tested whether Hsp40 could inhibit aggregation in 
the absence of its partner. We found that Hsp40 failed to block Aβ self-assembly, even at 
10-fold higher concentrations (50 nM) than those used in the previous experiments. 
Therefore, we conclude that, although both Hsp70 and Hsp70/40 prevent amyloid 
formation in vitro, the combination is most effective.  
2.2.3 Recombinant Hsp90 blocks aggregation of freshly prepared amyloid beta (1-
42)  
 
Although Hsp70 and Hsp40 have both been implicated in counteracting amyloid 
formation in certain neurodegenerative systems, Hsp90 has attracted less attention. In one 
in vitro model, Hsp90 has been shown to be insufficient to prevent amyloid formation.43  
However, Hsp90 is an important and highly abundant component of the chaperone 
machinery that shares some pro-folding tasks with other heat shock proteins.36, 37 To 
explore potential roles of this chaperone in Aβ aggregation, we performed similar 
experiments to those described in the preceding section. Similar to what we observed 
with Hsp70/40, Hsp90 provided a strong dose-dependent block to amyloid formation 
when added to freshly prepared Aβ samples (Figure 2-3). The peak of Hsp90’s anti-
aggregation activity was also observed at sub-stoichiometric concentrations (between 
1:50 and 1:200). TEM images revealed that Aβ in the Hsp90-treated samples was again 
re-directed into small, roughly circular structures instead of fibrils. Thus, both Hsp70/40 
and Hsp90 could partially prevent assembly of freshly prepared Aβ in vitro. 





 Because the ATP- and ADP-bound forms of Hsp70 have different affinities for 
peptide substrate,63 we sought to study the role of ATPase activity in preventing Aβ 




be important, but we sought additional evidence using a complementary approach. 
Therefore, the non-hydrolyzable ATP analog, ATPγS, was employed. Freshly prepared 
Aβ was treated with Hsp70/40 or Hsp90 in the presence of either ATP or ATPγS. 
Turbidity and thioflavin T measurements revealed that these chaperone’s inhibitory 
effects are partially disrupted by ATPγS (Figure 2-4). However, we found that Hsp70 had 
a stronger requirement for ATPase activity than Hsp90; ATPγS disrupted nearly all of 
Hsp70’s anti-aggregation activity, but over 50% of Hsp90’s function remained. Thus, 
these results suggest that the catalytic cycle of ATP hydrolysis is required for Hsp70’s 
anti-aggregation activity but that Hsp90 only partly depends on its enzymatic function. 
As part of these studies, we also were interested in determining if any protein 




amyloid formation with bovine serum albumin (BSA). At the highest concentrations used 
(474 nM, equivalent to the top chaperone levels employed), no effect on Aβ aggregation 
was observed (Figure 2-4). These results are consistent with previous reports using non-
chaperone proteins,43 and demonstrate that the chaperone interaction cannot be replaced 
by contacts with the BSA interface.  
2.2.5 An Hsp70 agonist promotes anti-aggregation activity  
Because our results indicate that ATPase activity is required for chaperones to 
fully block aggregation, we hypothesized that agonists (particularly those that promote 
turnover by Hsp70) might stimulate this function. The natural product analog, 15-
deoxyspergualin, is an agonist of Hsp70 that binds outside the nucelotide binding site 67-
69. Recent work by the Wipf, Day and Brodsky laboratories has shown that certain 
synthetically-accessible dihydropyrimidines, which structurally mimic 15-
deoxyspergualin, can likewise enhance ATPase activity and regulate protein 
translocation.55, 70 Based on these studies, we have recently developed a route to the 
modular synthesis of additional dihydropyrimidines and shown that some of these 
molecules modify Hsp70’s ATPase activity and it ability to refold denatured luciferase.71, 
72 During the course of those studies, we found that one of these compounds, SW02, 
enhanced ATPase activity and folding ability by at least 20% in vitro. Conversely, a 
related compound, SW08, blocked luciferase refolding by ~50%. More recently, we also 
identified the binding site of a dihydropyrimidine on Hsp70 and showed that these 
compounds alter interactions between Hsp70 and Hsp40.62 Importantly, these studies 
revealed how compounds with a similar core chemical structure can operate as either 




Based on these studies and the apparent importance of nucleotides, we 
hypothesized that SW02 (Figure 2-5A) might stimulate Hsp70’s ability to block Aβ 
aggregation and SW08 might be inhibitory.  To test this theory, we started with an Hsp70 
concentration, 119 nM, that was insufficient to block aggregation. Under these 
conditions, we propose that aggregation could only be inhibited if the chaperone activity 
were artificially enhanced.  When SW02 was added to this suboptimal chaperone pool, 
significant anti-aggregation activity was gained (Figure 2-5B). In control experiments, 
SW02 had no effect in the presence of Hsp40 or Hsp90.  Moreover, in the absence of any 
chaperone, SW02 did not alter Aβ aggregation.  Thus, these results suggest that SW02 is 




gain further evidence in support of this idea, we used a higher concentration of Hsp70 
(474 nM) and added the antagonist SW08. This treatment partially blocked Hsp70’s 
function and restored aggregation (Figure 2-5B). Thus, agonists and antagonists could be 
used to adjust or “tune” chaperone activity. 
2.2.6 The potency of SW02 is modest, but it enhances Hsp70/40 function  





level of Hsp70/40 (119 nM) and measured Aβ aggregation by turbidity and thioflavin T 
assays (Figure 2-6). In both platforms, we found that high concentrations of SW02 
(between 100 and 500 µM) were required to activate the chaperone. By TEM, treatment 
with Hsp70/40 and 500 µM compound yielded similar Aβ structures to those produced by 
treatment with higher concentrations of unstimulated chaperone (Figure 2-6C). Together, 
these results suggest that, although the potency of SW02 is modest, promoting 
Hsp70/40’s anti-aggregation activity can enhance inhibition in vitro. 
2.2.7 Chaperones recognize amyloid oligomers but have little effect on mature fibrils  
Despite the characteristic presence of Aβ fibrils in the brains of AD patients, 
recent evidence suggests that oligomers are critical in the development of disease. 
Therefore, we sought to determine if chaperones would have any effects on preformed 
oligomers or mature fibrils. The impetus for these experiments was to understand (in an 
in vitro system), the types of amyloid forms that can be recognized by chaperones. The 
answer to this question might provide insight into how chaperones counteract Aβ toxicity 
in vivo. Moreover, we (and others) have an interest in pharmacological stimulators of 
chaperone activity. These efforts would benefit from additional mechanistic knowledge 
about the types of amyloid structures that can be modified by chaperones. For example, if 
mature fibrils were dissolved by chaperones and processed into toxic oligomers, this 
could have a strongly negative effect on the organism. Moreover, if chaperones only act 
on freshly prepared Aβ samples (as used in Figures 2-1,-2, and -3 above), this suggests 
that pre-existing oligomers might be safe from chaperone intervention. Because of these 
questions, we decided to supplement our studies with experiments that explore the effects 




By varying the temperature and buffer conditions used to prepare Aβ, we were 
able to produce solutions of soluble oligomers or fibrils, consistent with previous 
reports.73, 74 After formation of these structures, chaperones and ATP were added and any 
effects measured by thioflavin T fluorescence and TEM. Treatment of preformed fibrils 
with Hsp70/40 or Hsp90 had little effect on the thioflavin T fluorescence (Figure 2-7). 
Because the native cellular environment might posses both of these chaperone systems, 




small, but not statistically significant drop in fluorescence. TEM results supported this 
observation; very little change in fibril structure was observed. However, in analyzing the 
samples, we noticed that the fibril length tended to be shorter in the Hsp70/40/90-treated 
samples (Figure 2-8). To further investigate this observation, we used image analysis to 
quantify average fibril length. Although this result is not striking, there was a slight 
tendency for chaperone-treated samples to contain fewer long fibrils. However, because 
this effect is subtle we conclude that these chaperones have very little impact on fibrils. 
Preformed oligomers were treated with chaperones and studied by thioflavin T 
fluorescence and TEM. Under these conditions, Hsp70/40 did not measurably change the 
thioflavin T reactivity or structure of oligomers (Figure 2-9). The combination of 




drop. Hsp90 alone could produce similar effects, but these changes were more 
pronounced in the triple chaperone-treated samples. To study the ultrastructure of the 
treated oligomers, we studied the resulting solutions by TEM. The oligomers in the 
samples treated for 240 minutes with Hsp70/40/90 become noticeably less defined and 
more diffuse (Figure 2-9). This effect was most obvious during attempts to focus the 
images; it wasn’t possible to capture images in which the oligomer boundaries were well 
defined. Additional experiments will be required to further characterize this effect, but 






2.3.1 Model for Hsp70’s potential roles in neurodegenerative disease 
Self-assembly of Aβ produces a number of distinctive structures, such as dimers, 
oligomers, unstructured aggregates and characteristic amyloid fibrils. Of these structures, 
oligomers are believed to be the most neurotoxic and important in the development of 
disease.3, 8, 9 Thus, any strategies to reduce amyloid-related phenotypes must avoid 
producing toxic oligomers from relatively benign structures, such as fibrils. In genetic 
models of AD, Hsp70/40 overexpression reduces cell death, which is a result that is 
consistent with decreased oligomer load. Moreover, in a D. melanogaster model of 
Huntington’s disease, Hsp70 overexpression inhibits neurodegeneration without 
preventing the formation of large inclusions.46  These results provide indirect evidence 
that chaperones specifically inhibit early stages of aggregation. However, we reasoned 
that biochemical support for this conclusion would enhance our understanding of the 
types of amyloid structures recognized by chaperones. These considerations led us to 
explore the interaction of chaperones with various types of Aβ structures in vitro. 
Specifically, we have studied the effects of Hsp70/40 and Hsp90 on three types of 
amyloid structures: freshly prepared Aβ, oligomers, and fibrils. Although the exact 
temporal and causal relationships between these structures are unclear, we use the freshly 
prepared samples and oligomers as representative of earlier stages in self-assembly. This 
distinction is partially based on the observation that aged Aβ preparations and terminal 
AD patient’s brains often contain elongated fibrils.75  Using this paradigm, we conclude 
that Hsp70/40 and Hsp90 specifically influence aggregation at “early” stages in the 




most susceptible, while fibrils were less affected (Figure 2-7). This result is consistent 
with findings in other systems that suggest an early role for chaperones in blocking 
protein aggregation.43, 50, 51 One interesting question related to this observation is whether 
samples treated with chaperones in vitro are neurotoxic. We have not characterized 
toxicity in this system, but chaperones are protective in other systems3, 8-10 and we predict 
that treated Aβ will also be less toxic. 
What is the molecular mechanism used by chaperones to inhibit Aβ self-
assembly? Although the details of this process remain unclear, we will discuss our results 
in the context of two specific models (Figure 2-10). In the “holding” model, the 
chaperone binds misfolded amyloid (likely via its substrate-binding domain). We propose 
that this interaction decreases free monomer concentration and, thereby, slow the rate of 
self-assembly, which is known to be dependent on monomer availability.75-77 This model 
predicts that inhibition would be independent of ADP-ATP exchange because cycles of 
substrate release do not contribute to the inhibitory mechanism. Some of our results are 
consistent with this prediction. Specifically, we report that Hsp90 is only partially 
inhibited by ATPγS. Thus, for this chaperone, we speculate that a “holding” or 
partitioning model describes some of the observations. However, Hsp90 was effective at 
substoichiometric concentrations (Figure 2-3). This result seems at odds with the 
“holding” model because one might presume that a 1:1 (or greater) stoichiometry should 
be optimal. The dependence of Aβ aggregation on monomer concentration might partly 
resolve this apparent conflict; decrease in available monomer is expected to directly 
influence rate. Thus, removal of monomer might be effective even if only a portion of the 








of competent monomer.78 Further analysis of this model awaits, but we cannot dismiss 
the possibility that Hsp70/40 partly accesses a “holding” mode and we consider it likely 
that Hsp90’s behavior is consistent with this mechanism. 
A more active role for chaperones is proposed in the “refolding” model (Figure 2-
10B). In this model, chaperones not only bind Aβ but they also change its structure; 
release from chaperone is coupled to conversion of Aβ to an altered state.  The altered 
structure is defined as being less competent for progression through the aggregation 
pathway (or, alternatively, better able to travel a non-productive route51). How would this 
structural modification occur? Some clues might be gleaned by studying Hsp70’s 
function during normal de novo protein biosynthesis. Current models suggest that Hsp70 
acts by “entropic pulling”;79 chaperone binding to extended polypeptides precludes 
certain entropically accessible conformations. Thus, the presence of Hsp70 forces the 
peptide to sample other conformations, which likely have fewer exposed hydrophobic 
regions. Therefore, under this model, chaperone would bind Aβ in an aggregation-prone 
state (i.e. exposed hydrophobic regions and primed for self-association) and release it in a 
modified conformation.  We propose that this model is consistent with our data on 
Hsp70.  For example, we found that Hsp70’s ATPase activity was required to inhibit 
aggregation (Figure 2-4) and that its potency could be stimulated by co-chaperone 
(Figure 2-2) or an agonist (Figure 2-5).  These results suggest that ATP-driven cycles of 
substrate binding-and-release are important.  Further, the “refolding” model predicts that 
a low molar ratio of chaperone could be effective if a single enzyme acts on multiple 
substrates. We found this to be true for both Hsp70/40 and Hsp90 (Figures 2-1 and -3). 




process Aβ in a “refolding” model. Whether this conclusion describes the behavior of 
other combinations of chaperones and misfolded peptides is unclear. 
An important aspect of both models (Figure 2-10) is that neither Hsp70/40 nor 
Hsp90 are effective at dealing with fibrils.  Based on our results (Figure 2-7) and 
observations from other systems,50, 51 we suggest that chaperones may have difficulty 
recognizing hydrophobic regions embedded in fibrils.  Alternatively, the interaction 
energy supplied by extensive monomer-monomer contacts may be an insurmountable 
barrier to chaperone-mediated reorganization (at least by the chaperones tested). 
Regardless, our results suggest that fibrils are not readily reversible by the action of 
Hsp70/40 or Hsp90.  Oligomers, on the other hand, seem susceptible to manipulation by 
the tri-chaperone system (Figures 2-7 and 2-9).  This suggests that these structures 
contain sufficiently exposed hydrophobic “flags” to trigger chaperone recognition and 
subsequent reorganization. 
Recently, an interesting hypothesis was developed by Morimoto and colleagues to 
explain the favorable effects of chaperone overexpression.80, 81 This “sink hypothesis” 
states that cellular toxicity might develop because chaperones and other proteins are 
being sequestered onto amyloid fibrils and re-directed from their normal tasks. Under this 
model, depleted cellular levels of these factors may trigger apoptosis by decreasing the 
levels below a threshold needed to maintain necessary processes.82 Thus, chaperone over-
expression might circumvent the problem by supplying a less exhaustible supply. 
Moreover, higher chaperone levels might block other proteins from becoming trapped by 
the “sink”. This intriguing hypothesis has been developed around work with Huntington’s 




example, we have shown that Hsp70/40 and Hsp90 can influence early stages of Aβ 
aggregation but that fibrils are not significantly changed.  Although direct evidence is still 
needed, these results suggest that chaperones might accumulate on fibrils because they 
are unable to process these structures. 
An interesting component of these discussions is whether oligomers and pre-
oligomeric Aβ are normally present in the same subcellular space as chaperones. 
Chaperones are expressed in all intracellular regions, including the nucleus, secretory 
pathway, and cytoplasm. Aβ fibrils are found in extracellular regions, but the exact 
location of oligomer production is unclear. Recent reports have examined extracellular83-
86 and intracellular18, 49, 54, 87-92 models. Thus, the exact mechanism by which the 
protective effect of chaperones is manifested awaits definition.  For example, it isn’t clear 
if chaperones simply provide a general cytoprotection or if direct physical interaction is 
required.  Regardless, our results strongly suggest that, if early Aβ structures are formed 
in the presence of Hsp70/40 or Hsp90, these proteins prevent further self-assembly.  
Our results support a hypothesis in which stimulation of chaperone activity may 
be a viable means of therapy for neurodegenerative diseases.  Previous studies to test this 
idea were conducted in mouse93, 94 and tissue culture95, 96 models of neurodegenerative 
disease. For example, an analog of the natural product, geldanamycin, was shown to 
promote the clearance of huntingtin in a mouse model of Huntington’s disease.  This drug 
is proposed to be anti-neurodegenerative by virtue of its ability to activate the 
transcription factor, heat shock factor-1 (HSF-1).93, 94  HSF-1 controls transcription of 
proteins involved in the stress response, including Hsp70.  Thus, geldanamycin may 




In another approach, Morimoto and colleagues screened a chemical library for 
compounds that could modify amyloid formation in a yeast model of Huntington’s 
disease.97 They reported the discovery of celastrols that, like geldanamycin, stimulate 
HSF-1 and inhibit amyloid formation. Both these strategies take advantage of cellular 
mechanisms for coping with stress. Here, we suggest a complementary approach that 
involves direct stimulation of Hsp70. Based on pioneering work,55, 70 we have 
synthesized an agonist of Hsp70 and tested its activity in vitro. This molecule, SW02, 
was able to compensate for insufficient chaperone levels and promote anti-aggregation 
activity.  Compounds that have this effect in vivo might activate endogenous Hsp70 and 
combat neurodegenerative diseases without concomitant involvement of a stress 
response, a result that is supported by more recent studies of SW02 and related 
dihydropyrimidines in mammalian models of tau deposition.97 One compelling aspect of 
this approach is that it relies on boosting a physiological mechanism that normally 




2.4 Experimental Procedures 
2.4.1 Preparation of Amyloid Beta  
Synthetic amyloid beta 1-42 (AnaSpec, San Jose, CA) was prepared for aggregation 
according to previously developed methods.73, 74 Briefly, lyophilized Aβ was resuspended 
in hexafluoroisopropanol (HFIP), dried under a nitrogen stream, and stored as a film at -
20 °C.  Immediately prior to use, Aβ was resuspended in DMSO to 10 mM and sonicated 
for 10 minutes.  For experiments in which early stages of aggregation were studied, these 
aliquots were rapidly brought to 25 µM in phosphate buffered saline (PBS) pH 7.2 and 
used immediately.  Oligomers were prepared by diluting the Aβ to 25 µM with phenol 
red-free DMEM-F12 and incubating for 24 hours at 4 °C without shaking.  Fibrils were 
similarly prepared by incubating 25 µM Aβ in PBS at 37 °C for 24 hours with vigorous 
shaking.  
2.4.2 Turbidity Measurements 
Human Hsp70, Hsp40, and Hsp90 were provided by Assay Designs (Ann Arbor, MI). 
Hsp70 (catalog number ESP-555) is endotoxin-free, recombinant, human protein 
expressed and purified from bacteria; Hsp40 (SPP-400) is also recombinant, human 
protein and from bacteria; Hsp90 (SPP-770) is human and purified from HeLa cells. 
Concentrated stocks (100x) of these proteins or buffer control were dispensed into the 
wells of 96-well, half-volume, clear bottom plates (Corning, NY).  To these solutions, Aβ 
in either PBS or DMEM-F12 was added.  In the final volume (75 µL), Aβ was present at 
approximately 25 µM, ATP or ATPγS at 9 mM, and the heat shock proteins at the 
indicated concentrations. Plates were immediately placed in a pre-warmed SpectraMax 




program began with a 20 sec mixing shake and was followed by absorbance readings at 
330 or 350 nm every 60 sec.  A 20 sec shaking step immediately followed each reading, 
followed by 40 seconds of settling time.  The temperature was set at 30 or 37 °C (see 
Figure legends). For Hsp70/40 treated samples, the listed concentration is the 
concentration of Hsp70 and the Hsp40 was held at 100-fold lower value.  For example, 
treatment with 474 nM Hsp70/40 involved final concentrations of 474 nM Hsp70 and 4.7 
nM Hsp40. 
2.4.3 Electron Microscopy 
At the conclusion of the turbidity measurements, 25 µL aliquots were removed from each 
well and immediately frozen at -80 °C.  Thawed samples were placed on glow-discharged 
Formvar-coated 300-mesh copper grids (Electron Microscopy Sciences) for 1 minute, 
washed twice with distilled water, and treated with 3% uranyl acetate for 1 minute. 
Images were taken at 80 kV at magnifications between 46,000x and 130,000x.  Image 
quantitation was performed with NIH Image using at least 10 random fields. 
2.4.4 Thioflavin T Experiments 
Immediately following removal of samples for electron microscopy, the remaining 
volume from the turbidity experiments (50 µL) was treated with 75 µL of freshly 
prepared 50 mM glycine pH 8.0 containing 25 µM thioflavin T.  After 10 min at room 
temperature, the fluorescence was measured on a SpectraMax M5 multimode plate reader 
using an excitation of 440 nm and emission of 490 nm (475 nm cut-off).  The reported 
values have been corrected by subtracting the background fluorescence of thioflavin T in 
the absence of amyloid.  




The synthesis route selected for the production of the dihydropyrimidine core was based 




First compounds such as SW02 were synthesized using the Biginelli reaction to yield the 
dihydropyrimidine THF.  Two equivalents of the β-keto ester ethylacetoacetate (4mmol) 
were added to one equivalent (2 mmol) each of 4-bromobenzaldehyde and the urea of γ-
aminobutryric acid.  Following five minutes of stirring, HCl (10 mol%) was added.  The 
reaction is allowed to stir for 48 hours and is then poured into ice water.  After stirring in 
water for 1 hour, the precipitate is filtered and the solid is re-crystallized from ethanol to 
afford pure product in 85-92% yield.  This intermediate (1 mmol) was then diluted into 
HMPA and an equal amount of 25% NaOH was added and it was allowed to stir at room 
temperature for 30 minutes.  Methyliodide (1.5 equiv, 1.5 mmol) was added and allowed 
to stir overnight (Scheme 2-2A).61 It gives about a 90% yield.  The other class of 
dihydropyrimidines was directly inspired from previously reported examples of Hsp70 
ligands. Rather than utilizing the Ugi reaction to produce a peptoid, the dihydropyrmidine 
was attached to small peptides (Scheme 2-2B). In this case β-amino acids (3eq, 0.75 
mmol), which are resistant to hydrolysis, were coupled to Wang resin (0.25 g, 0.25 
mmol)  under microwave conditions. Through iterative couplings with HOBt/DIC (5 eq, 
1.25 mmol) in DMF at 60 °C with microwave irradiation, di- and tripeptides were 
synthesized.  Following deprotection of the last Fmoc protected amino acid with 20% 
piperidine, the dihydropyrmidine (3 eq, 0.75 mmol) was coupled using HOBt/DIC (5 eq, 
1.25 mmol) in DMF at 80 °C in the microwave.61 The product was then cleaved off 
Wang resin using 50% TFA and purified on reverse phase HPLC to afford compounds 
such as SW08 (Scheme 2-2C).  The overall yield ranged from 1%-30%.  





tetrahydropyrimidine-5-carboxylate (SW02) : 1H δ (CDCl3) 7.43-7.41 (2H, d), 7.13-7.11 
(2H, d), 5.73 (1H, s), 5.33 (1H, s), 4.09 (2H, m), 3.89-3.63 (2H, d), 3.69 (3H, s), 2.55 
(3H, s), 2.27 (2H, m), 1.90-1.80 (2H, d), 1.20-1.16 (3H, t).  13C δ (CDCl3) 173.24, 
165.82, 153.29, 148.29, 142.28, 121.73, 104.32, 60.35, 53.44, 51.72, 41.89, 30.77, 24.71, 
16.03, 14.14. [M+H] e: 439.08, o: 439.1. Yield 82% overall. 
4-(5-((benzyloxy)carbonyl)-4-(2,4-dichlorophenyl)-6-methyl-2-oxo-3,4-
dihydropyrimidin-1(2H)-yl)butanoic acid (115-7c): 1H δ (d-DMSO) 12.16 (1H, bs), 8.02 
(1H, s), 7.57 (1H, s), 7.29 (1H, d), 7.27 (4H, m), 7.06 (2H, d), 5.64 (1H, s), 5.09-4.96 
(2H, dd), 3.85-3.60 (2H, d), 2.68 (3H, s), 2.21 (2H, m), 1.85-1.66 (2H, m).  13C δ (d-
DMSO) 174.36, 165.22, 152.16, 151.97, 140.15, 136.63, 133.40, 129.43, 128.55, 128.23, 
128.11, 127.81, 100.76, 65.41, 50.35, 31.17, 25.00, 16.03. [M+H] e: 477.09, o: 477.1. 
Yield 94% overall. 
Notes 
This work has been published as “Heat shock protein 70 and 90 inhibit early stages of 
amyloid beta-(1-42) aggregation in vitro,” Evans, C.E., Wisén, S., and Gestwicki, J.E., 
2006, 281(44), 33182-91. 
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Dihydropyridines Affect Tau Stability in Cellular Models of 




A series of dihydropyridines were identified that impact the accumulation of tau, an 
important target in Alzheimer’s disease. Interestingly, these compounds appeared to operate 
in a manner similar to the dihydropyrimidines SW02 and 115-7c described in Chapter 2. 
Based on these findings, the dihydropyridine collection was expanded using the Hantzsch 
multicomponent reaction to develop preliminary structure-activity relationships (SAR). 
These studies revealed the SAR in cultured neuronal cells, providing a path towards creating 
more potent derivatives. Finally, because of shortcomings in the existing enantioselective 
routes, we developed the first enantioselective, organocatalytic route to these four-component 
Hantzsch products. Using this route, we found that only one of the enantiomers reduced 
aggregation of polyglutamine in a yeast model, validating the synthetic approach. In 
summary, this chemical series provides a new set of probes that can be used to explore tau 
and polyglutamine processing in models of neurodegeneration. 
3.1.1 Introduction to Tau and Known Chemical Probes 
Tau is a microtubule-binding protein that accumulates in a number of 
neurodegenerative disorders, including some forms of frontotemporal dementia and 




are characterized by aggregation of hyperphosphorylated tau.  The presence of abnormal 
tau correlates with neuron loss and memory deficits in patients with AD and other 
tauopathies.4  Therefore, selectively reducing its levels might be an effective therapeutic 
strategy. 
Efforts towards that goal have largely focused on either inhibitors of tau 
aggregation,5, 6 inhibitors of its phosphorylation7 or compounds that stimulate chaperone-
mediated degradation.8-10 While each these strategies are potentially promising and well 
supported by genetic evidence, many of the compounds identified to date have relatively 
modest activity. For example, methylene blue (MB), which both inhibits tau aggregation5, 
6 and stimulates its degradation through heat shock protein 70 (Hsp70),8-10 has an EC50 
value of approximately 10 µM. Other promising compounds, such as the Hsp90 
inhibitors 17-AAG and EC1012, reduce tau levels but they also produce a robust stress 
response, which is expected to diminish their long-term efficacy.8-11 Thus, new 
compounds that counteract tau accumulation are needed. 
During pilot screens for small molecules that impact cellular tau levels, we 
identified the 1,4-dihydropyridine 4a (data not shown).  Interestingly, this scaffold bears 
structural resemblance to the dihydropyrimidines, such as 115-7c and SW02, that we 
explored in Chapter 2. Based on this finding, we sought to synthesize a focused collection 
of compounds related to 4a to facilitate characterization of structure-activity relationships 
(SAR). Towards that goal, we were attracted to the Hantzsch multicomponent reaction 
because of its high atom economy and suitability for combinatorial synthesis.  




Multicomponent reactions, such as the Biginelli,12-20 the Passerini,21 the Ugi,22 
and the Hantzsch, provide a wide variety of pharmaceutically-important heterocycles.14, 
23-33  For example, the Hantzsch reaction provides products with a variety of biological 
activities, including calcium channel antagonists, modulators of multi-drug resistence 
(MDR) proteins, 5-hydroxytryptamine (5-HT) receptor inhibitors and anti-
inflammatories.34-40 Beyond their myriad biological activities, Hantzsch dihydropyridines 
are also useful as synthetic tools for reducing imines to amines.41-44 The mechanism for 
the Hantzsch reaction is believed to consist of enamine formation due to the condensation 
between the amine and one of the 1,3-dicarbonyl components and the formation of an 
α,β-unsaturated carbonyl from the Knoevenagel-like condensation of the other 1,3-
dicarbonyl and aldehyde components. The enamine and the α,β-unsaturated carbonyl then 
undergo a Michael addition followed by a ring closing step to afford the 1,4-
dihydropyridine (Scheme 3-1). 
3.1.3 Known Enantioselective Methodology to Synthesize 1,4-Dihydropyridines 
While enantioselective Biginelli,45, 46 Mannich,47, 48 and Passerini49 reactions are 
well known, parallel methodologies have not been developed for the four-component 




refluxing ethanol, have made development of an asymmetric route challenging. For 
example, attempts to develop diasterioselective products with glycosylated enamines 
have yielded only modest selectivity (Scheme 3-2).50 With more recent advances in 
Lewis acid-catalyzed reactions,51 one  way  to   achieve   enantio-enrichment   is  to  use  
an enamine attached to a chiral auxillary in the presence of n-butyllithium (Scheme 3-
2).52  While the enrichment values for this method are good to excellent (~54 to 96%), 
this approach reduces the reaction to three components and limits the diversity of the 
products.  Because of the shortcomings of these routes and in response to our need for an 
expanded collection of dihydropyrimidines, we have developed a relatively benign and 
efficient method to four-component Hantzsch products by employing an organocatalyst, 






3.2 Results and Discussion 
3.2.1 Creation of a Dihydropyridine Library for SAR Studies 
Based on the structure of the active compound 4a, we first employed dimedone 1, 
ethylacetoacetate 2, ammonium acetate, and a series of functionalized aldehydes to create 
derivatives (Scheme 3-3).  Our goal was to vary specific functional groups on the 1,4-
dihydropyridine core to identify the key preliminary SAR for this series. We expected 
that these studies would facilitate identification of the target and, moreover, provide 




goal, a series of aldehydes were chosen to sample both bulky aromatics and smaller, alkyl 
functionalities. Briefly, dimedone (1.5 equiv), ethylacetoacetate (1 equiv), and Yb(OTf)3 
(10 mol%) were mixed in acetonitrile.  After stirring for 10 minutes, the aldehyde (1.0 
equiv) and ammonium acetate (1.0 equiv) were added.  The reactions then proceeded for 
3-5 hours, after which it was poured into saturated sodium chloride, washed with 
ethylacetate and the product was re-crystallized from 1:3 water:ethanol.  Using this 
approach, compounds 4a-r were obtained in moderate to good yields (ranging from 69-
94%). 
3.2.2 Further Modifications of the 1,4-Dihydropyridine Core 
To expand diversity in this collection, we took advantage of published methods53 
to exchange the ester for a thioester on representative compounds 4a and 4b.  Briefly, 
these examples were refluxed in toluene with 2.2 equivalents of Lawesson’s reagent for 1 




in good yield (Scheme 3-4).  
Next, to test whether modifications to the heterocyclic amine could be tolerated,  
we combined dimedone with aryl or alkyl amines in acetonitrile to form the enamine.54, 55 
After 30 minutes, ethylacetoacetate (1.0 eq), 2,4-dicholoro benzaldehyde 3a (1.0 eq) and 
10% Yb(OTf)3 were added and the reaction was allowed to proceed for an additional 4-5 





To further diversify the scaffold, we next varied the identity of the 1,3-
dicarbonyls (8 and 9; Scheme 3-6).  Specifically, we used indanedione and 2,4-
pentanedione in place of dimedone to produce derivatives 10a and 10b in good yields.  
On the other side of the molecule, we substituted either methylacetoacetate or 
benzylacetoacetate for ethylacetoacetate to produce 10c and 10d in 82 and 85% yield, 
respectively. 
Finally, to fully exploit the strengths of the Hantzsch reaction we varied multiple 




employed earlier, we made compounds 11a-11k (Scheme 3-7). These compounds include 
examples, such as 11b and 11c, which included β-ketoamides. Together, these efforts 
produced a library of 39 functionalized dihydropyridines. No attempts were made to 
control stereochemistry in these specific studies, and thus the compounds were purified 




3.2.3 Organocatalytic Method for Enantioselective Synthesis of Dihydropyridines  
To this point, our collection contained racemic mixtures. Because we were 
interested in whether one of the enantiomers might be more active than the other, we 
sought an enantio-enriched route to these products. As mentioned above, existing routes 
have significant drawbacks. Thus, we developed an enantioselective route to Hantzch 
dihydropyrimidines. As a model reaction, we selected a known polyhydroquinoline that 
would afford one stereocenter (Table 3-1). Consistent with previous reports, one 
equivalent dimedone (0.4 mmol), ethylacetoacetate, a benzaldehyde and ammonium 
acetate, in the presence of Yb(OTf)3 (10 mol%), produced product 4a in both ethanol and 
acetonitrile (entries 2-3, Table 3-1). Work-up consisted of precipitating with 1 mL of 
ice/water, stirring for approximately one hour, filtration of the precipitate and 
recrystallization of the product from a ethanol:water system (3:1 vol).  Using this 
procedure, we found good yields (68% in ethanol and 72% in acetonitrile), but the 
reaction also resulted in formation of the symmetrical side product. In an attempt to 
minimize this competing pathway, the equivalents of dimedone were increased (entries 4-
6, Table 3-1).  At 1.5 equivalents, the yield increased to 90% with concomitant reduction 
in the side product.  Next, we explored the influence of catalyst concentration by 
screening at 0.1, 1.0 and 5.0 mol%.  In each case, increasing the catalyst improved yield 
(52%, 65%, and 84%, respectively; entries 8-10 Table 3-1). Based on these observations, 
we selected reaction conditions of 1.5 equivalents (0.6 mmol) of dimedone, 1 equivalent 
(0.4 mmol) of ethylacetoacetate, ammonium acetate, and a substituted benzaldehyde with 




Using these conditions, our plan was to screen organocatalysts for those that 
would afford a high degree of enantioselectivity.  Chiral Lewis acids56-59 as well as 
proline and its derivatives56 have been explored in this context, but these have produced 
poor stereoselectivity.  Therefore, we sought to screen an expanded collection. In these 
studies, we used polarimetry to estimate enantio-enrichment and chiral HPLC to confirm 
these observations.  Consistent with the previous reports, proline derivative (I) provided 
good yields (86%) but poor enrichment.  Next, a series of phosphine based ligands 
(BINAP—II and III, DPPF—IV, and DPE—V) was explored.  These catalysts were used 




84% but no enantio-enrichment.  Finally, we synthesized60-62 and explored chiral BINOL-
phosphoric acid derivatives (VI and VII).  Both catalysts provided good yields (84-85%) 
and 98% ee (Table 3-2).  Thus, we were able to identify catalysts that supported a high 





One of the expected advantages of an enantioselective four-component Hantzsch 
reaction is in the combinatorial synthesis of substituted dihydropyridines.  To explore this 
possibility, we selected polar and non-polar substituted aldehydes with a range of 
electron withdrawing and donating groups and assembled a small collection of 16 





which employed 3,4-dihydroxybenzaldehyde, required modified work-up conditions; in 
these cases, the reactions were poured over brine and washed with ethylacetate prior to 
recrystallization. Otherwise, a uniform method involving 10 mol% catalyst VII was 
employed. These experiments revealed that most aromatic aldehydes proceed to the 
expected product in good yield (80-94%). Aromatic aldehydes with unprotected polar 
groups generally produced slightly lower yields (69-72%; compounds 4k and 4l).  As 
determined by HPLC, excellent enantioselective-enrichment (87 to >99%) was observed 
for all compounds.  Thus, from these studies, we identified a robust synthetic route for 
the four-component synthesis of 1,4-dihydropyrimidines. Next, we wanted to determine 
the SAR for the initial series to focus the enantioselective, synthetic efforts on more 
advanced derivatives. 
3.2.4 Preliminary SAR Obtained from Screening 
 With this collection of compounds in hand, we treated cultured IMR32 
neuroblastoma cells and measured endogenous tau levels by Western blot.63  We had 
previously found that the example 4a increased tau levels in these cells (data not shown) 
and sought to understand the SAR underlying these findings, to assist with target 
identification and biological studies. Although 4a had a significant impact on tau levels, 
its potency was modest (EC50 ~ 50 µM), necessitating further medicinal chemistry. 
Towards those goals, Dr. Umesh Jinwal in Chad Dickey’s group at University of 
South Florida treated IMR32 cells with compounds at 100 µM and, after 24 hours, the tau 
levels were compared to those in a mock treated control (1% DMSO).  Some of the 
compounds, such as 11b-f, were found to be toxic under these conditions and they were 




compounds MB and 17-AAG, which reduced tau levels by approximately 50 to 70%  
(Figure 3-1).8-11 Based on those values, we imposed an arbitrary threshold of 25% to 
focus on the most active compounds in the dihydropyridine collection. This approach 
revealed that 4p, 11a and 11g reduced tau levels by at least 25%. Interestingly, we also 
identified examples, such as 4a-b, 4d, 10b-c, 11j and 11k, which increased tau levels by 
at least 25%.  Previous efforts have also noted compounds that either increase or decrease 






An analysis of these results suggested some preliminary SAR (Figure 3-2).  
Specifically, large substitutions on the aldehyde, such as napthyl (4j), p-diphenyl (4o) or 
p-tert-butyl phenyl (4i), were not tolerated.  Likewise, conversion of the ester to a 
thioester in 5a and 5b reduced activity, as did any modification of the heterocyclic amine 
(compounds 7a-d). Modest substitutions of an ethyl to methyl group (e.g. from 4a to 10c) 
had marginal effect on activity but larger groups, such as the benzyl ester in 10d, 
abolished activity.  Interestingly, minimally functionalized benzyls in the aldehyde 
position, such as 4a, 4b and 4d, produced the most potent stimulators of tau 
accumulation, while smaller alkyl groups, such as in 4p, tended to produce compounds 
that reduced tau levels.  This finding suggests a way of converting a compound from one 
that causes tau accumulation to one that leads to tau reductions. However, the impact of 
modifications at the aldehyde position also seemed to be influenced by the identity of the 




accumulation, but replacing it for a methyl diketone, as in 11a and 11g, produced 
relatively strong inhibitors. Together, these findings reveal patterns of substitution that 
result in compounds that either promote tau degradation or accumulation. 
Following this initial screening, we selected compound 11g for dose response 
studies.  We found that this compound reduced tau levels by ~75% with an IC50 of ~7 µM 
(Figure 3-1B). This activity is comparable to some of the most potent anti-tau 
compounds, such as MB.8-10  As mentioned above, inhibitors of Hsp90, such as 17-AAG, 
have short-term effects on tau stability but they also induce a strong stress response.11   
To test whether 11g shares this property, we examined the levels of stress-inducible 
Hsp70 in the IMR32 cells.  By Western blots, Hsp72 levels were unchanged, suggesting 
that 11g does not act through the Hsp90 pathway (Figure 3-1B). The cellular target of 
these dihydropyridines is currently unclear, but the relatively good activity of 11g 
suggests that further studies are warranted. The follow-up studies should be facilitated by 
the SAR and enantioselective route established here. 
Further cell-based studies were carried out following the synthesis of 11g with 
both R and S enantiomers of the phosphoric acid BINOL catalysts, as described above.  
Comparable yields were obtained (82% and 85% with the R and S enantiomers, 
respectively) following flash column purification. A yeast polyglutamine assay was then 
used to screen which product was more active. In this model, longer repeats of glutamine 
(e.g. Q103), aggregate and the subcellular puncta can be visualized by the appended CFP 
tag. Cells were treated with the enantio-pure 11g derivatives (10 µM), which revealed 






3.3 Summary      
In summary, we have developed an enantioselective route for the Hantzsch 
reaction using a chiral phosphoric acid organocatalyst under relatively mild conditions 
and suitable for a wide range of aldehydes that has enabled us to synthesize 11g, a 
promising new compound that reduces tau levels by up to 70%. Recent studies indicate 
the one enantiomer of 11g is more active than the other, thus validating the synthetic 
route. This syntheitc method may find use in the synthesis of other medically important 
dihydropyridines and, potentially, as reagents for enantioselective hydrogenation 
reactions. Moreover, the dihydropyridine SAR may lead to improved potency and the 




3.4 Experimental Procedures 
3.4.1 Synthesis of Compounds 4a-4r (Scheme 3-3). 
Component 1 dimedone (1.5eq, 0.6mmol) and component 3 ethylacetoacetate 
(1eq, 0.4mmol) were suspended along with 10mol% VII in 1mL of acetonitrile. After 
stirring under inert gas for 10min, component 2 (1eq, 0.4mmol) and ammonium acetate 
(1eq, 0.4mmol) were added. The reaction was allowed to stir for 3-5h. All reactions 
except for 4d, 4f, 4k, 4l, and 4o were precipitated by the addition of ice/water. 
Following precipitation the reactions were recrystallized with an ethanol/water system. 
For the other reactions (4d, 4f, 4k, 4l, and 4o), the reactions were added to brine and 
extracted with ethylacetate. Following concentration, these products were also 
recrystallized with an ethanol/water system.  
3.4.2 Characterization of compounds 4a-4r.  
All NMR collected and analyzed on Varian 400MHz system using VnmrJ™ 
version 2.2 revision C. Samples diluted in CDCl3
Ethyl 4-(2,4-dichlorophenyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-
carboxylate (4a): 1H δ (CDCl3) 7.33-7.31 (1H, d), 7.24 (1H, s), 7.11-7.08 (1H, d), 6.53 
(1H, s), 5.33 (1H,s), 4.07-3.99 (2H, m), 2.30 (3H, s), 2.29-2.21 (2H, dd), 2.18-2.09 (2H, 
dd), 1.19-1.16 (3H, t), 1.06 (3H, s), 0.94 (3H, s).  13C δ (CDCl3) 195.38, 167.18, 149.44, 
142.38, 133.63, 132.83, 131.94, 129.13, 126.89, 111.07, 104.65, 60.09, 50.54, 40.90, 
32.78, 29.10, 27.41, 19.23, 14.42. [M+H] e: 408.11, o: 408.1. [α]D = +3.8 (c 2.19, 
CHCl3).  Yield 89-94%. 
 immediately prior to data collection. 
Mass spectrometry data collected on and Micromass LCT time-of-flight mass 




Ethyl 2,7,7-trimethyl-5-oxo-4-phenyl-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate (4b): 
1H δ (CDCl3) 7.3-7.29 (2H, d), 7.21-7.17 (2H, t), 7.11-7.07 (1H, t),5.93 (1H, s), 5.05 (1H, 
s), 4.08-4.03 (2H, m), 2.37 (3H, s),2.34- 2.2.22 (2H, dd), 2.21-2.13 (2H, dd), 1.21-1.17 
(3H, t), 1.07 (3H, s), 0.93 (3H, s).  13C δ (CDCl3) 195.36, 167.28, 147.72, 147.07, 143.43, 
112.32, 106.06, 59.77, 50.69, 41.19, 36.52, 32.64, 29.38, 27.14, 19.34, 14.19.  [M+H] e: 
340.18, o: 340.2.  [α]D = +16 (c 2.5, CHCl3).  Yield 82-85%.   
Ethyl 4-(4-bromophenyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-
carboxylate (4c): 1H δ  (CDCl3) 7.32-7.30 (2H, d), 7.18-7.16 (2H, d), 6.29 (1H, s), 5.00 
(1H, s), 4.08-4.03 (2H, m), 2.37 (3H, s), 2.35-2.23 (2H, dd), 2.21-2.12 (2H, dd), 1.20-
1.17 (3H, t), 1.07 (3H, s), 0.92 (3H, s).  13C δ (CDCl3) 195.36, 166.87, 148.88, 145.75, 
143.74, 131.07, 129.70, 111.38, 106.01, 59.85, 50.78, 40.90, 36.18, 32.47, 29.36, 26.85, 
19.23, 14.17.  [M+H] e: 418.09, o: 418.1.  [α]D = +4.1 (c 1.77, CHCl3).  Yield 80-84%. 
Ethyl 4-(3,5-dimethoxyphenyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-
carboxylate (4d): 1H δ (CDCl3) 6.55 (1H, s), 6.47 (2H, s), 6.23-6.22 (1H, t), 5.01 (1H, s), 
4.10-4.05 (2H, m), 3.72 (6H, s), 2.34 (3H, s), 2.31-2.25 (2H, dd), 2.22-2.15 (2H, dd), 
1.24-1.20 (3H, t), 1.05 (3H, s), 0.96 (3H, s).  13C δ (CDCl3) 195.54, 167.36, 160.26, 
149.35, 143.35, 111.63, 106.36, 105.83, 97.78, 59.78, 55.11, 50.61, 40.92, 36.57, 32.62, 
29.32, 27.18, 19.27, 14.28.  [M+H] e: 400.20, o: 400.2.  [α]D = +30 (c 1.96, CHCl3).  
Yield 72-74%. 
Ethyl 4-(3-fluorophenyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-
carboxylate (4e): 1H δ (CDCl3)  7.17-7.09 (2H, m), 6.99-6.95 (1H, d), 6.80-6.76 (2H, t), 




(2H, dd), 1.21-1.17 (3H, t), 1.07 (3H, s), 0.93 (3H, s).  13C δ (CDCl3) 195.37, 167.19, 
164.05, 161.57, 149.13, 143.51, 129.15, 114.77, 114.62, 112.92, 112.64, 111.64, 105.89, 
59.94, 50.38, 40.87, 36.49, 32.89, 29.37, 26.86, 19.42, 14.26.  [M+H] e: 358.17, o: 358.2.  
[α]D = +13 (c 2.53, CHCl3).  Yield 89-92%. 
Ethyl 4-(4-(dimethylamino)phenyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-
hexahydroquinoline-3-carboxylate (4f): 1H δ (CDCl3)7.18-7.16 (2H, d), 6.64-6.62 (2H, 
d), 6.44 (1H, s), 4.95 (1H, s), 4.09-4.04 (2H, m), 2.86 (6H, s), 2.34 (3H, s), 2.28-2.23 
(2H, dd), 2.19-2.11 (2H, dd), 1.24-1.20 (3H, t), 1.05 (3H, s), 0.94 (3H, s).  13C δ (CDCl3) 
195.93, 167.44, 148.32, 143.19, 128.58, 112.19, 109.95, 106.03, 59.85, 50.77, 40.90, 
35.29, 32.78, 29.65, 27.42, 19.23, 14.17.  [M+H] e: 383.23, o: 383.2.  [α]D = +29 (c 1.48, 
CHCl3).  Yield 75-78%.  
Ethyl 2,7,7-trimethyl-5-oxo-4-(2-(trifluoromethyl)phenyl)-1,4,5,6,7,8-
hexahydroquinoline-3-carboxylate (4g): 1H δ (CDCl3) 7.50-7.48 (1H, d), 7.45-7.43 (1H, 
d), 7.39-7.35 (1H, t), 7.22-7.18 (1H, t), 6.48 (1H, s), 5.60 (1H, s), 4.15-3.93 (2H, m), 
2.36-2.22 (2H, d), 2.28 (3H, t), 2.21-2.07 (2H, dd), 1.14-1.11 (3H, t), 1.05 (3H, s), 0.90 
(3H, s).  13C δ (CDCl3) 195.21, 167.40, 148.20, 146.05, 142.61, 131.34, 130.90, 127.45, 
126.64, 126.22, 112.35, 109.94, 107.30, 59.87, 50.39, 41.07, 33.50, 32.60, 29.16, 27.11, 
19.17, 13.96. [M+H] e: 408.17, o: 408.2.  [α]D = -4.4 (c 1.94, CHCl3).  Yield 79-85%.   
Ethyl 4-(2,5-difluorophenyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-
carboxylate (4h):  1H δ (CDCl3) 7.02 (1H, m), 6.84-6.74 (2H, m), 6.33 (1H, s), 5.19 (1H, 
s), 4.07-4.02 (2H, m), 2.38-2.26 (2H, dd), 2.34 (3H, s), 2.21-2.13 (2H, dd), 1.21-1.17 




154.80, 150.45, 146.22, 136.80, 116.91-116.73, 114.64-114.31, 108.90, 102.43, 59.49, 
50.51, 32.53-32.16, 29.45, 26.69, 18.66, 14.34.  [M+H] e: 376.16, o: 376.2.  [α]D = +5.5 
(c 1.89, CHCl3).  Yield 90-94%. 
Ethyl 4-(4-tert-butylphenyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-
carboxylate (4i): 1H δ (CDCl3) 7.18 (4H, s), 6.22, (1H, s), 5.02 (1H, s), 4.11-4.04 (2H, 
m), 2.37-2.26 (2H, dd), 2.34 (3H, s), 2.24-2.16 (2H, dd), 1.26 (9H, s), 1.21-1.19 (3H, t), 
1.07 (3H, s), 0.97 (3H, s). 13C δ (CDCl3) 195.92, 167.43, 148.32, 143.75, 143.19, 127.44, 
124.87, 112.20, 106.33, 59.84, 50.77, 41.23, 35.86, 34.52, 32.90, 31.34, 29.35, 27.40, 
19.23, 14.19.  [M+H] e: 396.25, o: 396.3.  [α]D = +12 (c 1.95, CHCl3). Yield 84-88%. 
Ethyl 2,7,7-trimethyl-4-(naphthalen-2-yl)-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-
carboxylate (4j): 1H δ (CDCl3) 7.74-7.67 (4H, m), 7.50 (1H, d), 7.38-7.35 (2H, t), 6.52 
(1H, s), 5.22 (1H, s), 4.07-4.02 (2H, m), 2.41 (3H, s), 2.21-2.19 (2H, dd), 2.14-2.06 (2H, 
dd), 1.21-1.17 (3H, t), 1.10 (3H, s), 0.87 (3H, s).  13C δ (CDCl3) 195.53, 167.36, 148.88, 
144.41, 143.55, 133.34, 132.21, 127.37, 126.28, 125.06, 111.81, 106.07, 59.82, 50.03, 
40.91, 36.80, 32.57, 29.40, 27.01, 19.38, 14.20.  [M+H] e: 390.20, o: 390.2.  [α]D = +8.5 
(c 2.14, CHCl3).  Yield 81-83%. 
Ethyl 4-(4-cyanophenyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-
carboxylate (4k):   1H δ (CDCl3) 7.51-7.49 (2H, d), 7.43-7.41 (2H, d), 6.29 (1H, s), 5.09 
(1H, s), 4.07-4.01 (2H, m), 2.40 (3H, s), 2.34-2.25 (2H, d), 2.21-2.12 (2H, dd), 1.18-1.14 
(3H, t), 1.07 (3H, s), 0.90 (3H, s).  13C  δ (CDCl3) 195.28, 166.82, 152.21, 148.79, 
144.23, 131.82, 128.88, 119.25, 111.15, 109.58, 105.06, 60.00, 50.46, 40.98, 37.25, 
32.70, 29.31, 27.04, 19.39, 14.14.  [M+H] e: 365.18, o:365.2.  [α]D = +5.0 (c 1.21, 





carboxylate (4l): 1H δ (CD3OD) 6.68 (1H, s), 6.54 (2H, s), 4.84 (2H, s), 4.81 (1H, s), 
4.06-4.00 (2H, m), 3.28 (1H, s), 2.42-2.24 (2H, dd), 2.31 (3H, s), 2.19-2.06 (2H, dd), 
1.20-1.17 (3H, t), 1.04 (3H, s), 0.91 (3H, s).  13C δ (CD3OD) 197.11, 168.20, 150.85, 
144.09, 142.91, 139.29, 118.91, 114.87, 111.05, 105.53, 59.40, 50.00, 39.65, 35.49, 
32.03, 28.17, 25.73, 17.12, 13.14.  [M+H] e: 371.17, o: 372.2.  [α]D = +4.1 (c 1.56, 
MeOH).  Yield 69%. 
Ethyl 2,7,7-trimethyl-5-oxo-4-phenethyl-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate 
(4m): 1H δ (CDCl3) 7.25-7.08 (5H, m), 6.33 (1H, s), 4.21-4.00 (3H, m), 2.57-2.48 (2H, 
m), 2.23 (3H, s), 2.30-2.25 (2H, d), 2.20-2.16 (2H, d), 1.59-1.82 (2H, m), 1.29-1.25 (3H, 
t), 1.10 (3H, s), 1.08 (3H, s).  13C δ (CDCl3) 195.96, 189.42, 167.77, 149.81, 144.48, 
142.99, 128.21, 125.37, 116.31, 110.94, 105.04, 59.74, 50.86, 46.17, 37.96, 31.16, 27.18, 
19.30, 14.38.  [M+H] e: 368.21, o: 368.2.  [α]D = +4.2 (c 1.61, CHCl3).  Yield 92-94%. 
Ethyl 4-(2-chlorophenyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-
carboxylate (4n): 1H δ (CDCl3) 7.39-7.37 (1H, d), 7.24-7.22 (1H, d), 7.13-7.09 (1H, t), 
7.03-7.00 (1H, t), 6.76 (1H, s), 5.38 (1H, s), 4.07-4.00 (2H, m), 2.33-2.23 (2H, dd), 2.27 
(3H, s), 2.18-2.08 (2H, dd), 1.19-1.15 (3H, t), 1.05 (3H, s), 0.93 (3H, s).  13C δ (CDCl3) 
195.61, 167.44, 149.44, 143.73, 133.09, 129.68, 127.13, 126.34, 110.83, 110.27, 105.21, 
59.29, 50.55, 40.89, 35.84, 32.48, 29.10, 27.10, 18.98, 14.17.  [M+H] e: 374.14, o: 374.1.  
[α]D = +8.6 (c 1.67, CHCl3).  Yield 89-94%. 
Ethyl 4-(biphenyl-4-yl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-




6.50 (1H, s), 5.10 (1H, s), 4.10-4.05 (2H, m), 2.38 (3H, s), 2.36-2.26 (2H, dd), 2.22-2.14 
(2H, dd), 1.23-1.20 (3H, t), 1.07 (3H, s), 0.95 (3H, s).  13C δ (CDCl3) 195.60, 167.40, 
148.87, 146.12, 143.51, 141.13, 138.75, 128.57 126.91, 111.87, 106.11, 59.85, 50.63, 
41.00, 36.30, 32.71, 29.39, 27.19, 19.35, 14.21.  [M+H] e: 416.21, o: 416.2.  [α]D = +12 
(c 1.75, CHCl3).  Yield 72-77%. 
Ethyl 4-sec-butyl-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate 
(4p): 1H δ (CDCl3) 6.11 (1H, s), 4.21-4.10 (2H, m), 4.08-4.07 (1H, d), 2.31-2.24 (4H, 
dd), 2.30 (3H, s), 2.22-2.18 (1H, dd), 1.37-1.30 (2H, m), 1.29-1.26 (3H, t), 1.08 (6H, d), 
0.87-0.83 (3H, t), 0.73-0.71 (3H, t).  13C δ (CDCl3) 196.27, 168.36, 143.91, 110.37, 
104.75, 59.66, 50.96, 43.23, 41.27, 32.38, 29.87, 27.00, 25.56, 19.08, 14.67, 12.29.  
[M+H] e: 320.21, o: 320.2. [α]D= -0.33 (c 2.4, CHCl3). Yield 66%.    
Ethyl 2,4,7,7-tetramethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate (4q): 1H δ 
(CDCl3) 6.19 (1H, s), 4.21-4.10 (2H, m), 3.93-3.88 (1H, dd), 2.31-2.14 (4H, dd), 2.28 
(3H, t), 1.29-1.25 (3H, t), 1.07-1.06 (6H, d), 0.99-0.97 (3H,d).  13C δ (CDCl3) 195.83, 
167.70, 149.08, 143.68, 112.63, 106.99, 59.64, 50.81, 41.00, 32.66, 29.47, 26.97, 25.44, 
19.24, 14.38.  [M+H] e: 278.17, o: 278.2.  [α]D= +0.67 (c1.48, CHCl3).  Yield 72%.    
Ethyl 2,7,7-trimethyl-5-oxo-4-(1,4-dioxaspiro[4.5]decan-2-yl)-1,4,5,6,7,8-
hexahydroquinoline-3-carboxylate (4r): 1H δ (CDCl3) 5.83-5.66 (1H, d), 4.32-4.30 (1H, 
m), 4.26-4.11 (2H, m), 3.99-3.92 (1H, m), 3.84-3.79 (1H, m), 3.73-3.66 (1H, m), 2.44-
2.16 (4H, t), 1.55-1.43 (6H, dd), 1.38-1.20 (4H, m), 1.15-1.05 (3H, t).  [M+H] e: 404.24, 
o: 404.2. Yield 75%. 
3.4.3 Synthesis of Compounds 5a-b (Scheme 3-4). 




(1eq, 0.4mmol) were suspended along with 10mol% Yb(OTf)3
3.4.4 Characterization of Compounds 5a-b. 
 in 1mL of acetonitrile. 
After stirring under inert gas for 10min, component 2 (1eq, 0.4mmol) and ammonium 
acetate (1eq, 0.4mmol) were added. The reaction was allowed to stir for 3-5h. All 
reactions were precipitated by the addition of ice/water. Following precipitation the 
reactions were recrystallized with an ethanol/water system.  The product was then 
added to a round bottom flask diluted with toluene and Lawesson’s reagent (2.2 equiv) 
was added and the reaction was refluxed for 1-2 hours.  The resulting product was 







) 7.33‐7.31 (1H, d), 7.24 (1H, s), 7.11‐7.08 (1H, d), 6.53 
(1H, s), 5.33 (1H,s), 4.07‐3.99 (2H, m), 2.30 (3H, s), 2.29‐2.21 (2H, dd), 2.18‐2.09 (2H, 




3.4.5 Synthesis of Compounds 7a-d (Scheme 3-5), 10a-d (Scheme 3-6), and 11a-k 
(Scheme 3-7). 
) 7.3‐7.29 (2H, d), 7.21‐7.17 (2H, t), 7.11‐7.07 (1H, t),5.93 (1H, s), 
5.05 (1H, s), 4.08‐4.03 (2H, m), 2.37 (3H, s),2.34‐2.2.22 (2H, dd), 2.21‐2.13 (2H, dd), 
1.21‐1.17 (3H, t), 1.07 (3H, s), 0.93 (3H, s). [M+H] e: 356.16, o: 356.2. Yield 82‐85%.  
The synthesis of compounds 7, 10, and 11 necessitated adding the amine (1 eq, 




components were then stirred for 30 minutes.  The catalyst Yb(OTf)3 (10 mol %), the 
aldehyde (1 eq, 0.4 mmol), and 1,3-diketone (1.5 eq, 0.6 mmol) were then added to the 
reaction vessel and allowed to stir for the required amount of time.  The reactions were 
added to brine and extracted with ethylacetate. Following concentration, these products 
were also recrystallized from ethanol.     
3.4.6 Characterization of Compounds 7a-d, 10a-d, and 11a-k.  
4-(4-(2,4-dichlorophenyl)-3-(ethoxycarbonyl)-2,7,7-trimethyl-5-oxo-5,6,7,8-
tetrahydroquinolin-1(4H)-yl)butanoic acid (7a): 1H δ (CDCl3)  11.87, 7.39-7.09 (2H, dd), 
7.06-6.95 (1H, d), 5.61-5.51 (1H, t), 4.84- 4.74 (1H, t), 3.21-3.11 (2H, t), 2.52-2.38 (6H, 
m), 2.35-2.29 (3H, t), 2.27-2.17 (2H, dd), 2.12-1.94 (2H, dd), 1.25-1.20 (4H, t), 1.15-0.99 
(12H, d), 0.99-0.88 (3H), t).  [M+H] e: 494.14, o: 494.1. Yield 71%. 
Ethyl 4-(2,4-dichlorophenyl)-1-(4-hydroxybutyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-
hexahydroquinoline-3-carboxylate  (7b): 1H δ (CDCl3) 7.32-7.25 (2H, m), 7.24-6.98 (1H, 
m), 4.91 (1H, bs), 4.15-3.97 (2H, m), 3.09-2.82 (2H, bd), 2.47 (3H, m), 2.42-2.15 
(2H,m), 2.07-1.97 (1H, t), 1.58-1.46 (3H, t), 1.30-1.25 (2H, d), 1.24-0.83 (10H, m).  
[M+H] e: 480.16, o: 480.2. Yield 74%. 
Ethyl 4-(2,4-dichlorophenyl)-1-(3-hydroxyphenyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-
hexahydroquinoline-3-carboxylate (7c): 1H δ (CDCl3) 7.60-7.58 (1H, d), 7.38-7.29 (1H, 
m), 7.25-7.04 (2H, m), 7.04-6.93 (2H, m), 6.78-6.53 (1H, dd), 6.44-6.34 (1H,dd), 5.63 
(1H, s), 5.46 (1H, d), 4.15-4.05 (2H, m), 2.39-2.19 (2H, dd), 2.15-2.08 (2H, d), 2.08-2.05 
(3H, s), 1.97-1.89 (1H, t), 1.28-1.24 (2H, t), 1.19-1.02 (3H, t), 0.98-0.84 (6H, d).  [M+H] 





hexahydroquinoline-3-carboxylate (7d): 1H δ (CDCl3) 7.31-6.72 (9H), 5.31 (1H, s), 5.06-
5.00 (2H, q), 2.32-2.25 (3H, s), 2.24-2.12 (3H, dd), 2.10-2.04 (2H, dd), 1.08 (3H, s), 
0.96(3H, s).  [M+H] e: 498.15, o: 498.2. Yield 77%. 
Ethyl 4-(2,4-dichlorophenyl)-2-methyl-5-oxo-4,5-dihydro-1H-indeno[1,2-b]pyridine-3-
carboxylate (10a): 1H δ (CDCl3) 7.93-7.10 (7H), 5.36 (1H, t), 4.09-3.98 (2H, m), 2.78-
2.68 (3H, t), 2.39-2.24 (2H, dt), 1.34-1.28 (3H, m), 1.10-0.86 (3H, m).  [M+H] e: 414.06, 
o: 414.1. Yield 71%. 
Ethyl 5-acetyl-4-(2,4-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3-carboxylate 
(10b): 1H δ (CDCl3) δ 7.31-7.09 (3H), 6.15 (1H, s), 5.43-5.33 (1H, t), 4.13-4.07 (2H, m), 
2.32-2.28 (3H, t), 2.22-2.12 (6H, t),1.32-1.22 (3H, t).  [M+H] e: 368.07, o: 368.1. Yield 
75%. 
Methyl 4-(2,4-dichlorophenyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-
carboxylate (10c): 1H δ (CDCl3)  7.35-7.16 (2H, m), 7.11-7.04 (1H, m), 6.44 (1H, bs), 
5.38-5.28 (1H, t), 3.83-3.54 (3H, t), 2.37-2.27 (3H, t), 2.24-2.05 (4H, d), 1.24-1.02 (3H, 
t), 1.00-0.80 (3H, t).  [M+H] e: 394.09, o: 394.1. Yield 82%.    
Benzyl 4-(2,4-dichlorophenyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-
carboxylate (10d): 1H δ (CDCl3) 7.31-6.99 (7H, m), 6.98 (1H, d), 6.72 (1H, s), 5.31 (1H, 
s), 5.03- 5.00 (2H, q), 2.27 (3H, t), 2.25-2.16 (4H, d), 2.12-2.04 (2H,dd), 1.08-1.03 (3H, 
t), 0.98-0.91 (3H, t).  [M+H] e: 470.12, o: 470.1. Yield 85%. 
Benzyl 5-acetyl-4-(2,4-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3-carboxylate 
(11a): 1H δ (CDCl3) 7.38-7.10 (8H), 6.28 (1H, t), 5.43 (1H, t), 5.21-5.11 (2H, t), 2.39-





dihydropyridine-3-carboxamide (11b): 1H δ (CDCl3) 8.20 (1H, s), 7.31-7.21 (3H), 6.90 
(1H, m), 5.39 (1H, s), 3.77-3.60 (2H, dq), 3.18-2.96 (6H, m), 2.81 (3H, t), 2.37-2.30 (3H, 
dd), 1.99-1.58 (10H, m), 1.30-1.17 (3H, m).  [M+H] e: 435.15, o: 435.2. Yield 82%. 
5-acetyl-N-(4-(tert-butyl)benzyl)-4-(2,4-dichlorophenyl)-2,6-dimethyl-1,4-
dihydropyridine-3-carboxamide (11c):  1H δ (CDCl3) 7.34-7.09 (7H, m), 5.37 (1H, t), 
4.12-4.09 (2H, m), 3.08-2.66 (2H, dd), 2.54-2.28 (3H, m), 2.27-2.13 (6H, m), 1.41-1.15 
(9H, m).  [M+H] e: 485.17, o: 485.2. Yield 76%. 
Ethyl 5-acetyl-4-(2,4-dichlorophenyl)-1-(4-hydroxybutyl)-2,6-dimethyl-1,4-
dihydropyridine-3-carboxylate (11d): 1H δ (CDCl3) 7.41-7.09 (3H, m), 4.63- 4.55 (1H, 
m), 4.09 (2H, m), 2.56 (2H, m), 2.26-1.80 (4H, m), 1.76-1.59 (6H, t), 1.30-1.22 (6H, t), 
1.18-1.03 (3H, m).  [M+H] e: 440.13, o: 440.1. Yield 69%. 
Ethyl 5-acetyl-1-benzyl-4-(2,4-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3-
carboxylate (11e) 1H δ (CDCl3) 7.36-7.19 (8H), 4.49 (1H, d), 4.44-4.40 (2H, m), 4.38 
(2H, m), 3.47-3.37 (3H, t), 2.29 (6H, t), 1.99 (3H, t).  [M+H] e: 458.12, o: 458.1. Yield 
82%. 
Ethyl 5-acetyl-2,6-dimethyl-4-(naphthalen-2-yl)-1,4-dihydropyridine-3-carboxylate (11f): 
1H δ (CDCl3) 7.76-7.39 (7H), 6.23 (1H, t), 5.20 (1H, t), 4.19-4.14 (3H, m), 2.39-2.33 
(3H, t), 2.28-2.19 (6H, t), 1.34-1.24 (3H, m).  [M+H] e: 350.17, o: 350.2. Yield 71%. 
Ethyl 5-acetyl-4-(4-bromophenyl)-2,6-dimethyl-1,4-dihydropyridine-3-carboxylate (11g): 
1H δ (CDCl3) 7.35-7.24 (2H, m), 7.18-7.08 (2H, m), 6.19 (1H, t), 5.01-4.96 (1H, m), 
4.17-4.08 (2H, m), 2.36-2.25 (6H, t), 2.23-2.18 (3H, t), 1.30-1.18 (3H, m).  [M+H] e: 




Ethyl 5-acetyl-4-(3-fluorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3-carboxylate (11h): 
1H δ (CDCl3) 7.31-7.13 (, 7.01, 7.00, 6.99, 6.98, 6.72, 5.31, 5.06, 5.03, 5.03, 5.00, 4.12, 
4.11, 2.32, 2.27, 2.25, 2.24, 2.22, 2.20, 2.17, 2.16, 2.12, 2.10, 2.08, 2.07, 2.07, 2.06, 2.04, 
2.04, 1.27, 1.27, 1.26, 1.25, 1.24, 1.24, 1.08, 1.07, 1.03, 0.98, 0.96, 0.94, 0.93, 0.91.   
[M+H] e: 318.14, o: 318.1. Yield 82%. 
Ethyl 5-acetyl-2,6-dimethyl-4-(4-(pyridin-2-yl)phenyl)-1,4-dihydropyridine-3-
carboxylate (11i): 1H δ (CDCl3) 7.76-7.39 (7H), 6.23 (1H, t), 5.20 (1H, t), 4.19-4.14 (3H, 
m), 2.39-2.33 (3H, t), 2.28-2.19 (6H, t), 1.34-1.24 (3H, m).  [M+H] e: 377.18, o: 377.2. 
Yield 79%. 
Ethyl 5-acetyl-2,4,6-trimethyl-1,4-dihydropyridine-3-carboxylate (11j): 1H δ (CDCl3) 
5.86 (1H, s), 4.24-4.15 (2H, m), 3.81 (1H, m), 2.32-2.14 (9H, t), 1.36-1.23 (3H, m), 1.01-
0.90 (3H, t).  [M+H] e: 238.14, o: 238.1. Yield 71%. 
Ethyl 5-acetyl-4-(sec-butyl)-2,6-dimethyl-1,4-dihydropyridine-3-carboxylate (11k): 1H 
NMR δ (CDCl3) 5.72 (1H, t), 4.25-4.12 (2H, m), 3.93-3.89 (1H, m), 2.63-2.51 (1H, m), 
2.37-2.18 (9H, t), 1.44-1.17 (6H, m), 1.01-0.77 (3H, m), 0.77-0.65 (2H, m).  [M+H] e: 
280.18, o: 280.2. Yield 74%. 





(S)-2,2'-dimethoxy-1,1'-binaphthyl (628.8mg, 2mmol) was added to 20mL of anhydrous 
dichloromethane.  Once cooled down to 0°C, bromine (0.23mL, 4.5mmol) was added to 
the solution.  After 1 hour, the solution was poured into 30 mL of saturated NaHSO3.  
The mixture stirred for 1 hour.  It was then extracted three times with dichloromethane.  
The organic layers were combined and dried over Na2SO4, filtered, and then 
concentrated.  (S)-3,3'-dibromo-2,2'-dimethoxy-1,1'-binaphthyl (789.9mg, 1.7mmol), 
tris(dibenzylideneacetone) dipalladium (70mg, 0.077mmol), tricyclohexylphosphine 
(71.5mg, 0.255mmol), potassium fluoride (612.3mg, 10.54mmol), and an aryl boronic 
acid (5.1mmol) were added to a flame dried round bottom flask and 10mL of anhydrous 
tetrahydrofuran was added.  For catalyst VI phenylboronic acid was employed while for 
catalyst VII 3,5-dimethylphenylboronic acid was employed.  The reaction was allowed to 
reflux for 18 hours for both catalysts.  Following cooling down to room temperature the 
reaction was diluted with ethylacetate and then filtered through a pad of celite.  The 
organic was then concentrated and purified by a flash chromatography on silica.  The 




and 82% yield for the catalyst VII precursor.  Following the Suzuki coupling the methyl 
ether protecting group was removed by adding BBr3 (for catalyst VI precursor 1.3415g, 
5.36mmol and for catalyst VII 1.2188g, 4.865mmol) to the Suzuki product and stirring in 
50mL dichloromethane at 0°C for 1 hour.  It was allowed to warm to room temperature 
and then stirred for an additional 1 hour at room temperature.  Water was then added to 
the reaction.  The mixture was then diluted with dichloromethane.  The organic layer was 
then dried over Na2SO4.  The products were filtered and concentrated.  Then they were 
purified by silica flash chromatography and eluted at 25:75 ethylacetate:hexanes.  The 
yields obtained were 78% for the catalyst VI precursor and 81% for the catalyst VII 
precursor.  Both unprotected catalyst precursors were dissolved in 3mL pyridine.  To 
catalyst VI precursor 364.9mg (2.38mmol) of POCl3 were added and stirred under 
nitrogen for 5 hours.  To catalyst VII precursor 346.5mg (2.26mmol) of POCl3 were 
added under nitrogen for 5 hours.  After that time 3mL of water were added to each of the 
reactions.  The reaction was stirred for 30 minutes.  The reaction was then diluted with 
dichloromethane and was extracted with 1M HCl.  The organic phases were dried over 
Na2SO4 and concentrated.  The products were then purified by silica flash 
chromatography.  The products eluted at 10:90 MeOH:CH2Cl2.  The yield of catalyst VI 
was 75% yield (overall yield 0.89mmol, 44.5%) and for catalyst VII was 81% (overall 
yield 0.92, 46%).           
3.4.8 Characterization of Catalysts VI and VII 
All NMR collected and analyzed on Varian 400MHz system using VnmrJ™ 




collection.  Mass spectrometry data collected on and Micromass LCT time-of-flight mass 
spectrometer in the ES+ mode. 
Catalyst VI: 1H δ (d-DMSO) 8.443 (2H, s), 8.276-8.253 (2H, d), 7.855-7.835 (4H, d), 
7.793-7.771 (2H, d), 7.610-7.588 (2H, d), 7.546-7.489 (4H, m), 7.438-7.395 (4H, m).  
[M+H] e: 501.12, o: 501.1. 
Catalyst VII: 1H δ (CDCl3) 8.12 (2H, s), 8.00-7.95 (3H, d), 7.58 (3H,s),  7.48-7.45 (4H, 
m), 7.33 (4H, s ), 7.04 (2H, s), 2.41 (12H, s).  [M+H] e: 557.18, o: 557.2. 
Notes 
This work has been published as "Enantioselective Organocatalytic Hantzsch Synthesis 
of Polyhydroquinolones," Evans, C.G. and Gestwicki, J.E., Org Lett, 2009, 11(14), 2957-
9 and "Identification of Dihydropyridines That Reduce Cellular Tau Levels," Evans, 




Christopher G. Evans, Dr. Umesh K. Jinwal, Dr. Chad A. Dickey, and Dr. Jason E. 
Gestwicki designed the experiments; 
Christopher G. Evans synthesized the dihydropyridine library and the phosphoric acid 
BINOL catalysts, chiral HPLC analysis, polarimetry, and quantification Western blot 
data; 
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Improved Synthesis of 15-Deoxyspergualin and Its Analogs: Targeting 
the C-Terminus of Hsp70 and Hsp90 
 
4.1 Abstract 
 Derivatives of the immunosuppressive, natural product, spergualin,1, 2  are used in 
the clinic to treat acute allograft rejection, either as a stand-alone agents or in 
combination with other immunosuppressives.3-11  Biochemical evidence suggests that 
these compounds bind the C-terminus that is common to both Hsp70 and Hsp90. 
However, the molecular consequences of this interaction are not clear and the 
mechanisms of spergualin-mediated immunosuppression remain unknown.12-15 Progress 
towards these goals is complicated by the cumbersome synthesis of spergualin analogs, 
its limited availability for research use and the poor chemical stability of the products. To 
overcome these challenges, we have re-investigated the synthesis of spergualin and 
designed a route that reduces the number of synthetic steps and improves the overall yield 
by at least 6-fold. This route employs the Ugi multi-component reaction to generate the 
peptoid-like core of spergualin. This approach facilitates rapid and modular generation of 
derivatives, including the clinically important derivatives, 15-deoxyspergualin (15-DSG) 
and 15-methoxyspergualin (MeDSG). When compared to spergualin, products of this 
reaction have dramatically improved stability in both basic and acidic conditions. 




mechanisms of this class, including the discovery that spergualin-like compounds inhibit 
interactions between Hsp70 and the important E3 ligase, CHIP, likely by shielding 
contacts at the chaperone’s C-terminus. Thus, this improved synthetic route allows for the 
improved creation of spergualin derivatives. This advancement should permit new studies 
of their mechanism of action. 
4.1.1 Introduction to Spergualin and Its Analogs 
 As discussed briefly in Chapter 1, Umezawa and colleagues first identified 
spergualin in 1982 and characterized its antibiotic activity (Figure 4-1A).16, 17,18-21 This 
polyamine natural product was isolated from a soil sample and found to originated from a 
species similar to Bacillus lateroporus. Later work established that spergualin was a 
potent immunosuppressive, prolonging the survival of mice undergoing allograft 
rejection.  
Based on these promising biological activities, the total synthesis of spergualin 
was conducted by Kondo et al. using L-lysine and 3-amino-1-propanol as the starting 
materials in a convergent synthesis (Scheme 4-1A).  Briefly, L-lysine was converted to 
(S)-7-guanidino-3-hydroxyheptamide over nine steps, while 11-amino-1,1-dihydroxy-




two intermediates were then condensed under acidic conditions for a 14% overall yield.22  
Using this approach, a series of derivatives were produced, which revealed initial 
structure-activity relationships (SAR). Specifically, the 7-guanidino-3-hydroxyacyl and 
spermidine groups were found to be essential for activity.18-20 However, the hydroxyl 
group at carbon 15 was found to be dispensable and, moreover, removing this group to 
create 15-deoxyspergualin (15-DSG) appeared to significantly improved stability in basic 
buffer (Figure 4-1B). Despite this improvement, 15-DSG was first synthesized in a poor 
0.3% yield.20 Later synthetic efforts, also employing a convergent route, mildly improved 
the yield to around 7% (Scheme 4-1B).23, 24   
 
4.1.2 Analogs of 15-Deoxyspergualin 
 Given the promising activity of spergualin and 15-DSG, more recent attempts 




derivatives with better potency and produce compounds with less susceptibility to 
degradation (Scheme 4-2A).25, 26 Early studies of 15-DSG metabolism had suggested that 
it hydrolyzed to glyoxylspermidine and 7-guanadinoheptamide, especially in basic, 
aqueous buffer.17, 1825  Thus, Umeda et al. focused on replacing the unstable 
hydroxyglycine as carbon 11 with variety of amino acids while Lebreton et al. focused on 
switching this group to a carbamate (Scheme 4-2B).25, 28   These studies revealed that 
substitutions with serine, alanine, or glycine retained activity, while the larger 
phenylalanine was not tolerated.18, 27 Together, these efforts led to the identification of 
tresperimus (Figure 4-1C), which has improved stability compared to 15-DSG, while 




produced through a 14-step, complicated synthetic route, which resulted in poor yield 
(7%) and loss of the chiral center at position 11. We envisioned that an alternative would 
be to use the Ugi multi-component reaction, followed by a subsequent reductive 
amination, to produce the spermidine core, thus yielding a 15-DSG analog in fewer 
synthetic transformations and with retention of the chiral center (Scheme 4-2C).30 
4.1.3 The Hsp70-15-Deoxyspergualin Interaction 
 When potential use of 15-DSG analogs would be in the exploration of its 
mechanism of action. Although these compounds are potent immunosuppressants and 
they are used in the clinic, their mechanisms are still unknown. Current models suggest 
that Hsp70 and Hsp90 are among the cellular targets of 15-DSG.31, 32 Sugawara et al. 
proposed that 15-DSG inhibits the activation of dendritic cells by interacting with 
Hsp70.33  This activity is thought to be mediated by interactions between spergualin 
derivatives and the EEVD motif found at the C-terminus of both Hsp70 and Hsp90. 
Removing this motif from Hsp70 ablated the effect of 15-DSG.  Further, Nadler et al. 
identified Hsc70, a mammalian constitutively expressed member of the Hsp70 family, as 
the cellular target of 15-DSG in pull-down assays and the EEVD motif was found to be 
required.34, 3536  The Kd for the interaction between Hsc70 or Hsp90 and 15-DSG has 
been determined to be  approximately 5 µM.37, 38  
4.2 Results and Discussion 
4.2.1 Application of the Ugi Reaction to Create Spergualin Analogs 
 The Ugi reaction allows synthesis of a peptoid backbone from four components, a 
carboxylic acid, amine, isocyanide, and aldehyde or ketone.17, 40-44  This reaction is used 




for high throughput screening.45-47 The first step is thought to be the formation of the 
imine by the condensation of the amine and the aldehyde or ketone, followed by proton 
transfer from the carboxylic acid to form the iminium ion and attack by the isocyanide.  
To complete the reaction, the carboxylic acid then adds to the isocyanide and the peptoid 
is obtained through a five-membered ring intermediate (Scheme 4-3).     
 As envisioned, our Ugi-based synthesis of spergualin analogs would proceed 
through the synthesis of two key components: guanidinylated amines and a series of 
isocynanides. The first component was generated using the method reported by 
Feischtingnder et al., who used N,N’-di-Boc-N’’-triflylguanidine as the guanidinylating 




procedure was slightly modified (Scheme 4-4).  Briefly, a flame-dried round bottom flask 
containing 1 mmol of the amino acid was diluted with 8 mL of anhydrous 
dichloromethane (DCM).  Then, N-methyl-N-trimethylsilyl-trifluoroacetamide (2.2 
mmol) was added, and the reaction was heated to a reflux under an argon atmosphere.  
Upon clarification of the solution, it was cooled and triethylamine (1.1 mmol) and N,N’-
di-Boc-N’’-triflylguanidine (1.1 mmol) were added. The reaction was then stirred at 
room temperature for 4-5 hours, diluted with DCM and washed with brine and water.  
Following drying with sodium sulfate, the mixture was concentrated and purified by flash 
column chromatography (eluted 50:50 ethylacetate:hexanes). Using this procedure, a 
series of intermediates was developed, varying in the length of their alkane chains. The 
yields for the guanidinylation of aminoheptanoic acid, aminohexanoic acid, and γ-
aminobutyric acid ranged from 64-75% (2, Scheme 4-4).   
 To create the isocynamide-based intermediate for the Ugi reaction and satisfy the 
known SAR findings, we pursued 1, 4-diaminobutane (1, 4-DAB). Because DAB has two 
equivalent amines, we first mono-protected one of these using literature precedent.51  
Briefly, 1, 4-DAB (7.5 g, 85.08 mmol) was diluted in 30 mL of dioxane. A solution of di-
tert-butyldicarbonate (2.4 g, 11 mmol) in 30 mL of dioxane was then added to the stirring 
1, 4-DAB drop-wise over 1.5 hours.51 This reaction was stirred for 24 hours and the 
solvent removed under vacuum. To this mixture, 50 mL of water was added and the 
resulting insoluble material was removed by filtration.  The filtrate was extracted three 
times with 45 mL of DCM.  The organic layers were dried with sodium sulfate and 




 The next step in the generation of tert-butyl (4-isocyanobutyl)carbamate is the 
addition of formic acid to the remaining free amine group (Scheme 4-5A).  Towards that 
goal, tert-butyl (4-aminobutyl)carbamate (2 mmol) was diluted in 5 mL DCM and formic 
acid (2 mmol) was added to the stirring reaction.  The reaction was then placed into an 
ice-bath.  Once cooled, DIC (2 mmol) was added to the solution and the mixture stirred 
for 4 hours at room temperature.  The reaction was filtered and the filtrate was washed 
with saturated sodium bicarbonate solution.52  The organic layer was then dried with 
sodium sulfate and concentrated.  The resulting product, tert-butyl (4-aminobutyl)-
carbamate, was synthesized in 90-92% yield.  Tert-butyl (4-aminobutyl)carbamate (8.7 
mmol) was diluted with 13 mL of DCM.  Triethylamine (26.2 mmol) was then added and 
the solution was cooled in an ice-bath.  POCl3 (8.7 mmol) was then added dropwise.  The 
reaction was stirred for 30 minutes and then potassium carbonate (8.7 mmol) was added 
(Scheme 4-5A).  The reaction was then stirred for another 30 minutes.  The aqueous layer 
was extracted five times with DCM 5 times.  The DCM layers were combined, then 
washed with water, dried with sodium sulfate, and concentrated.52  The product was then 
purified by flash column chromatography (eluting at 50:50 ethylacetate: hexanes) giving 




phenyl)carbamate from mono-Boc- 1, 4-phenylenediamine as a way of adding rigidity to 
the four carbon linker of the spermidine tail (Scheme 4-5B).     
4.2.2 Developing the Methodology for the 15-Deoxyspergualin Core with the Ugi 
Reaction 
 
 Using these key intermediates, we next wanted to develop optimized conditions 
for the Ugi reaction. Many conditions for this reaction have been reported and recent 
studies have focused on using microwave irradiation to improve yield and reaction 
times.53, 54 To explore the best conditions for 15-DSG derivatives, we first used the 
commercially available isocyanide 1-isocyanopentane as a model reactant. Briefly, the 
solution of benyzlamine (0.1mmol), benzaldehyde (0.1 mmol), 6-guanidinohexanoic acid 
(1.1 mmol), and 1-isocyanopentane (0.1 mmol) was heated in 0.5 mL methanol (MeOH) 
using a Biotage Initiator microwave at 120 °C for 20 minutes (Scheme 4-6).  This process 
yielded the product in 70% yield following column purification using silica gel (eluting 
75:25 ethylacetate:hexanes).  However, when tert-butyl (4-isocyanobutyl)carbamate was 
substituted in the reaction, the yield decreased to a less desirable 11%.  Therefore, we 






 In this effort, we focused on three variables, reaction time, temperature, and 
solvent. Using the common microwave-compatible solvents, methanol, DMF and 
ethanol, we screened at temperatures from 90 to 120 °C for 10 to 20 minutes. This search 
identified DMF, 100 °C for 20 minutes as the best conditions, yielding 46% yield (Table 
4-1).   
 Following this optimized protocol, the library of 15-DSG analogs was 
synthesized. To build diversity in the series while also maintaining the previous SAR 
features, the aldehyde component was systematically varied while the 7-




held constant (entries 21-24, Table 4-2). Another set of derivatives was synthesized by 
varying the aldehyde component while 6-guanidinoheptanoic acid, benzylamine, and tert-
butyl (4-isocyanobutyl)carbamate were held constant (entries 1-12, Table 4-2).  Finally, 
three derivatives were synthesized using tert-butyl (4-isocyanophenyl)carbamate as the 
isocyanide (entries 3-4, Table 4-2).  Given that earlier publications had suggested the 
spermidine tail was important for 15-DSG’s activity, several truncated versions were 
synthesized (entries 1-2, Table 4-2) by deprotecting the Ugi reaction product with 85% 
phosphoric acid to remove the Boc groups.55  The benzyl group was then removed under 
oxidative conditions by CAN (2.1 equiv) in a water/acetonitrile (1/5 ratio) over 2 hours.56 
Following purification on basic alumina oxide and eluting with 10:90 
methanol:chloroform, the truncated product was isolated in 50-56% yield.  All products 
were deprotected using 85% phosphoric acid to prepare the free amine for the subsequent 
reductive amination to produce the full spermidine tail.55             
4.2.3 Producing the Spermidine Tail Employing a Reductive Amination Strategy 
 To complete the 15-DSG analogs, we envisioned reductive amination with Fmoc-
3-amino-1-propanal. This compound is readily available from Fmoc-β-alanine (Scheme 
4-7). Briefly, Fmoc-β-alanine (3 mmol, 1 equiv) was added to a flame dried round bottom 
flask, followed by dilution with 20 mL anhydrous DCM. Then triphenylphosphine (6 




β-alanine appeared to be consumed, N-O-dimethylhydroxylamine hydrochloride (6.3 
mmol, 2.1 equiv) and pyridine (15 mmol, 5 equiv) were added at 0 °C.  After 1 hour, the 
reaction was washed with brine and dried over sodium sulfate.  After concentration, the 
product, N-methoxy-N-methyl-3-(Fmoc-amino)-propionamide, was purified by flash 
column chromatography (eluting at 50:50 ethylacetate:hexanes) to give a 97% yield.58  
N-methoxy-N-methyl-3-(Fmoc-amino)-propionamide (1.15 mmol, 1 eq) was dissolved in 
10 mL anhydrous THF.  The reaction was cooled to -78 °C under an argon atmosphere.  
3.45 mL of a 1.0 M solution of diisobutylaluminum hydride in THF was added dropwise 
over 10 minutes. After 5 minutes the reaction was quenched with 5% HCl in EtOH and it 
was allowed to warm to room temperature. The solution was diluted into DCM and 
washed with brine, the organic layers were treated with sodium sulfate and then 
concentrated under vacuum. The product was then purified by flash column 
chromatography (eluting with 50:50 ethaylacetate:hexanes) to afford Fmoc-3-amino-1-
propanal in 62% yield. 
To conduct the reductive amination (Scheme 4-8) the phosphoric acid55 
deprotected Ugi products was employed as the amine (0.05 mmol, 1 equiv) and was 
diluted in 2 mL THF or DCE.  Then Fmoc-3-amino-1-propanal (0.05mmol, 1 equiv) was 
added to the reaction, followed NaBH(OAc)3 (0.07  mmol, 1.4 equiv). NaBH(OAc)3 was 
chosen for this study because it doesn’t require low pH’s like NaBH3CN and the 
chemical stability of 15-DSG analogs has proven to be a hurdle in the past.57  Moreover, 
NaBH(OAc)3 appears to provide a broader scope to the reaction, while generating less 
side product.57 The reaction containing NaBH(OAc)3 was allowed to stir for 1.5 hours 




the product extracted with ethylacetate, dried over sodium sulfate, and concentrated by 
vacuum.  The crude product was column purified on basic alumina oxide, eluting with 
10:90 methanol:ethylacetate.  The yield for this step generally ranged from 80-94% 
(entries 3-12, Table 4-2).  
4.2.4 Deprotection Strategy 
 Following reductive amination, the Fmoc group needed to be removed to produce 
the 15-DSG derivatives. One common way to remove Fmoc groups is with base, such as 
20% piperidine in DMF. However, we found that the stability of the products under these 
conditions was not optimal and, moreover, the cleaved Fmoc adduct needed to be 
removed by column chromatography. To circumvent similar issues, Tris(2-
aminoethyl)amine has been reported to remove Fmoc groups.59  Guided by those efforts, 
we stirred Tris-amine resin (50 equiv) with the 15-DSG analog in CHCl3 for 20 minutes.  
This time was required to allow for complete scavenging of the 9-methylene-9H-fluorene 




 Finally, removal of the benzyl group was carried out using mild conditions and 
CAN.56 In this method, CAN (2.1 equiv) is added to the 15-DSG analog in a solution of 
1:5 water:acetonitrile (2 mL). After stirring for 2 hours, the reaction is quenched with 
saturated sodium bicarbonate, stirred for 10 minutes and extracted with ethylacetate.  The 
organic layers were combined, dried over sodium sulfate and concentrated under vacuum.  
The product is then purified on a basic alumina oxide column (eluting at 10:90 
methanol:ethylacetate) to afford the final product (Table 4-2).     




 One of our major goals in this study was to produce sufficient quantities of 
spergualin derivatives to permit more detailed studies into its mechanism of action. 
Preliminary findings support the feasibility of this idea. For example, a fellow graduate 
student, Matt Smith, found that treatment of yeast cells with MeDSG (compound 13a), 
significantly decreased the aggregation of a polyglutamine construct (Fig 4-2).  This 
result suggests that the spergualin derivatives will be useful, membrane-permeable probes 
of Hsp70 and Hsp90 function in cells. 
  






 Another problem of the spergualin scaffold that we had hoped to address was its 
poor intrinsic, chemical stability.  Previous studies had shown that 15-DSG had a half-life 
of a few hours in basic buffers.  It has hoped that by changing the hydroxyl at position 11, 
a more stable derivative could be synthesized.  Towards that goal, methoxy-15-DSG 
(13a) was synthesized where the hydroxyl at position 11 was now a methoxy group.  We 
found that this subtle change greatly improved the stability of this compound (Figure 4-
3).  Thus it appears that the Ugi reaction/reductive amination strategy has provided small 
molecules that address our concerns about both potency and stability.  Hopefully with 
these contributions it will be able to use these small molecules to parse out Hsp70’s and 
Hsp90’s roles in neurodegeneration.  
4. 3 Summary 
In this work, a rapid method for producing 15-DSG analogs was developed.  The 
overall yields ranged from 29-56%, which is a significant improvement over the previous 
7% yields.  The key transformation in the new route is the Ugi reaction to generate the 
core peptoid in a single step.  Unlike the previous, liner routes, this multi-component 
approach is amenable to combinatorial chemistry and diversity can be quickly installed. 




proteins in cellular models of neurodegeneration.  This is an important step, which could 
improve our knowledge of the biology that occurs at the C-terminus of Hsp70 and Hsp90. 




4.4 Experimental Methods 
4.4.1 Synthesis of Guanidinylated Amino Acids (2) 
A flame-dried round bottom flask containing 1 mmol of the amino acid was 
diluted with 8 mL of anhydrous dichloromethane (DCM).  Then, N-Methyl-N-
trimethylsilyl-trifluoroacetamide (2.2 mmol) was added, and the reaction was heated to a 
reflux under an argon atmosphere.  Once the solution became clear, the reaction was 
cooled and triethylamine (1.1 mmol) and N,N’-di-Boc-N’’-triflylguanidine (1.1 mmol) 
were added to the stirring reaction.  The reaction stirred at room temperature for 4-5 
hours.  After the reaction reached completion, it is diluted with DCM and washed with 
brine and water.  Following drying with sodium sulfate the mixture was concentrated and 
purified by flash column chromatography (eluted 50:50 ethylacetate:hexanes).  The 
yields for the guanidinylation of aminoheptanoic acid, aminohexanoic acid, and γ-
aminobutyric acid ranged from 64-75%.   
4.4.2 Characterization of Guanidinylated Amino Acids  
4-(2,3-bis(tert-butoxycarbonyl)guanidino)butanoic acid (2a, n=2): 1H NMR (CDCl3) δ 
11.4 (1H, bs), 8.56 (1H, s), 2.93 (2H, s), 2.41 (2H ,s), 1.89 (2H, s), 1.41 (18H, s). 13C 
NMR (CDCl3) δ 176.61, 162.70, 156.76, 153.10, 83.63, 79.95, 39.74, 31.71, 28.40, 
25.30. [M+H] e: 346.19, o: 346.2. 
6-(2,3-bis(tert-butoxycarbonyl)guanidino)hexanoic acid (2b, n=4):  1H NMR (CDCl3) δ 
11.4 (1H,bs), 8.34 (1H, s), 3.39 (2H, s), 2.94 (1H, s), 2.35 (2H, s), 1.64-1.58 (4H, d), 1.48 
(18H, s). 13C NMR (CDCl3) δ 178.92, 163.31, 156.08, 153.23, 83.14, 79.39, 40.67, 33.76, 




7-(2,3-bis(tert-butoxycarbonyl)guanidino)heptanoic acid (2c, n=5): 1H NMR (CDCl3) 
11.4 (1H, bs), 8.32 (1H, s), 3.38 (2H, s), 2.94 (1H, s), 2.32 (2H, s), 2.62 (4H, d), 1.55 
(18H, s), 1.35 (4H, s). 13C NMR (CDCl3) δ 178.80, 156.02, 153.25, 83.15, 79.70, 40.87, 
33.79, 28.71, 28.58, 26.40, 24.45. [M+H] e: 388.24, o: 388.2. 
4.4.3 Synthesis of Isocyanides (6) 
To mono-protect 1, 4-DAB, 1, 4-DAB (7.5 g, 85.08 mmol) was diluted in 30 mL 
of dioxane.  A solution of di-tert-butyldicarbonate (2.4 g, 11 mmol) that was diluted in 30 
mL of dioxane was added to the stirring 1, 4-DAB dropwise over 1.5 hours.  The reaction 
was allowed to stir for 24 hours.  The solvent was then removed under vacuum and 50 
mL of water was added.  Any insoluble material was filtered off  and the filtrate was 
extracted with 45 mL of DCM three times.  The organic layers were dried with sodium 
sulfate and concentrated to give a 56-61% yield. 
 The next step in the generation of tert-butyl (4-isocyanobutyl)carbamate is the 
addition of formic acid to the remaining free amine group (Scheme 4-).  Tert-butyl (4-
aminobutyl)carbamate (2 mmol) was diluted in 5 mL DCM and formic acid (2 mmol) 
was added to the stirring reaction.  The reaction was then placed into an ice-bath.  Once 
cooled, DIC (2 mmol) was added to the solution and the mixture stirred for 4 hours at 
room temperature.  The reaction was filtered and the filtrate was washed with saturated 
sodium bicarbonate solution.  The organic layer was then dried with sodium sulfate and 
concentrated.  The resulting product, tert-butyl (4-aminobutyl)carbamate, was 
synthesized in 90-92% yield.  Tert-butyl (4-aminobutyl)carbamate (8.7 mmol) was 
diluted with 13 mL of DCM.  Triethylamine (26.2 mmol) was then added and the 




reaction stirred for 30 minutes at which time potassium carbonate (8.7 mmol) was added 
to the stirring reaction.  The reaction was then stirred for another 30 minutes.  The 
aqueous layer was extracted with DCM 5 times.  The DCM layers were then washed with 
water, dried with sodium sulfate, and concentrated.  The product was then purified by 
flash column chromatography (eluting at 50:50 ethylacetate: hexanes) giving a 72-76% 
yield.  The same procedure was used to synthesize tert-butyl (4-isocyanophenyl)-
carbamate from mono-Boc- 1, 4-phenylenediamine as a way of adding rigidity to the four 
carbon linker of the spermidine tail.     
4.4.4 Characterization of Isocyanides 
tert-butyl (4-isocyanobutyl)carbamate (6a): 1H NMR (CDCl3) δ 8.48 (1H, s), 3.40 (2H, 
s), 3.13 (2H, s), 2.22-2.01 (2H, d), 1.35 (9H, s), 1.17-1.10 (2H, d). 13C NMR (CDCl3) δ 
164.35, 155.95, 79.50, 41.19, 39.40, 28.34, 22.89. [M+H] e: 199.14, o: 199.1. 
tert-butyl (4-isocyanophenyl)carbamate (6b): 1H NMR (CDCl3) δ 7.39-8.38 (2H, d), 
7.29-7.26 (2H, d), 6.70 (1H, s), 1.50 (9H, s). 13C NMR (CDCl3) δ 163.02, 152.22, 
139.35, 127.14, 118.55, 81.31, 28.33. [M+H] e: 219.11, o: 219.1. 
4.4.5 Synthesis of Fmoc-aminopropanal (12) 
The first step is to add Fmoc-β-alanine (3 mmol, 1 equiv) to a flame dried round 
bottom flask then diluting the amino acid with 20 mL anhydrous DCM.  Then 
triphenylphosphine (6 mmol, 2 equiv) and trichloroacetonitrile (6 mmol, 3 equiv) were 
added.  After the Fmoc-β-alanine appeared to be consumed , N-O-dimethyl-
hydroxylamine hydrochloride (6.3 mmol, 2.1 equiv) and pyridine (15 mmol, 5 equiv) 
were added at 0 °C.  After 1 hour, the reaction was washed with brine and dried over 




propionamide, was purified by flash column chromatography (eluting at 50:50 
ethylacetate:hexanes) to give a 97% yield.  N-methoxy-N-methyl-3-(Fmoc-amino)-
propionamide (1.15 mmol, 1 eq) was dissolved in 10 mL anhydrous THF.  The reaction 
was cooled to -78 °C under an argon atmosphere.  3.45 mL of a 1.0 M solution of 
diisobutylaluminum hydride (3 equiv) in THF was added dropwise over 10 minutes.  
After 5 minutes the reaction was complete and 5% HCl in EtOH was added to quench the 
reaction, and the reaction was then allowed to warm to room temperature.  The solution 
was diluted into DCM and washed with brine.  The organic layers were sodium sulfate 
and then concentrated under vacuum.  The product was then purified by flash column 
chromatography (eluting with 50:50 ethaylacetate:hexanes) to afford Fmoc-3-amino-1-
propanal in 62% yield. 
4.4.6 Characterization of Fmoc-3-amino-1-propanal (12) 
1H NMR (CDCl3): δ 9.83 (1H, s), 7.78 (2H, d), 7.60 (2H, d), 7.33 (4H, m), 5.3 (1H, bs), 
4.40 (2H, d), 4.20 (1H, t), 3.52 (2H, t), 2.76 (2H, t). 13C NMR (CDCl3) δ 190.55, 155.40, 
143.73, 141.26, 127.66, 127.00, 125.00, 119.95, 60.40, 47.17, 20.92, 14.17. [M+H] e: 
296.12, o: 296.1.  
4.4.7 Synthesis of 15-Deoxyspergualin Analogs (9 and 13) 
The optimized conditions for the Ugi reaction consisted of the mixing of 
benyzlamine (0.1mmol), benzaldehyde (0.1 mmol), 6-guanidinoamino acid (1.1 mmol), 
and tert-butyl (4-isocyanobutyl)carbamate (0.1 mmol)  in 0.5 mL of MeOH and then 
heating the reaction using a Biotage Initiator microwave at 120 °C for 20 minutes. 
Tris(2-aminoethyl)amine has been published to remove Fmoc groups.  Using 




analog in CHCl3 for 20 minutes.  This time was required to allow for complete 
scavenging of the 9-methylene-9H-fluorene byproduct of Fmoc cleavage. 
 The removal of the final protecting group involves the removal of the benzyl 
group from the nitrogen of the amide backbone of the 15-DSG core structure.  One 
method that seemed less harsh and would remove the benzyl group rather quickly was 
through the oxidative capabilities of CAN.  In this method CAN (2.1 equiv) is added to 
the 15-DSG analog that is in a solution of 1:5 water:acetonitrile (2 mL).  After stirring for 
2 hours, the reaction is quenched by the addition of saturated sodium bicarbonate and 
stirred for 10 minutes.  The solution is then extracted with ethylacetate.  The organic 
layers were then dried over sodium sulfate and concentrated under vacuum.  The product 
is then purified on a basic alumina oxide column (eluting at 10:90 methanol:ethylacetate) 
to afford the final product. 
4.4.8 Characterization of 15-Deoxyspergualin Analogs 
N-(2-((4-aminobutyl)amino)-1-methoxy-2-oxoethyl)-6-guanidinohexanamide (9a): 1H 
NMR (CDCl3) δ 8.09 (2H, s), 5.88 (1H, s), 4.32 (3H, d), 3.41-3.06 (6H, d), 2.26 (2H, s), 
1.41 (6H, m), 1.19-1.06 (4H, m). Overall yield 52%. 
N-(2-((4-aminobutyl)amino)-1-(4-bromophenyl)-2-oxoethyl)-6-guanidinohexanamide 
(9b): 1H NMR (CDCl3) δ 8.03 (2H, s), 7.81-7.69 (2H, d), 7.63-7.57 (2H, d), 5.82 (1H, s), 
4.42 (2H, s), 4.04 (2H, s), 3.41-2.98 (4H, m), 2.25-2.17 (2H, m), 1.97 (2H, s), 1.42 (4H 
,m), 1.20 (4H, m), 0.86 (2H, d). Overall yield 57%. 
N-(2-((4-((3-aminopropyl)amino)butyl)amino)-1-methoxy-2-oxoethyl)-7-




(2H, d), 4.10-3.75 (2H ,d), 3.31 (3H, d), 3.13 (2H, s), 2.70 (6H ,s), 2.32-2.03 (8H, m), 
1.64-1.51 (10H, m) 1.25-1.14 (4H ,m). Overall yield 41%.   
N-(2-((4-((3-aminopropyl)amino)butyl)amino)-1-(4-bromophenyl)-2-oxoethyl)-7-
guanidinoheptanamide (13b): 1H NMR (CDCl3) δ 8.16 (2H, s), 7.79 (2H, d), 7.51 (2H, 
d), 5.82 (1H, s), 4.56-4.18 (4H, m), 4.15 (2H, s), 3.20 (2H, s), 3.05 (2H, s), 1.54-1.49 
(6H, m), 1.19 (6H, s), 0.86 (2H, s). Overall yield 33%. 
N-(1-((4-((3-aminopropyl)amino)butyl)amino)-1-oxopropan-2-yl)-6-
guanidinohexanamide  (13c): 1H NMR (CDCl3) δ 8.16 (2H, s), 5.82 (1H ,s), 4.60 (2H, s), 
4.38 (2H, s), 3.31 (4H, d), 3.13 (6H, s), 1.65-1.53 (6H, m), 1.14 (h$, d), 0.83 (5H, d).  
Overall yield 38%. 
N-(1-((4-((3-aminopropyl)amino)butyl)amino)-3-methyl-1-oxopentan-2-yl)-6-
guanidinohexanamide (13d): 1H NMR (CDCl3) δ 8.16 (2H, s), 5.83 (1H, s), (3.48 (4H, d), 
3.13 (4H, s), 1.27 (6H, s), 1.53 (8H, s), 1.48 (16H, s), 1.25 (3H, s). Overall yield 44%. 
N-(2-((4-((3-aminopropyl)amino)butyl)amino)-1-(4-bromophenyl)-2-oxoethyl)-6-
guanidinohexanamide (13e): 1H NMR (CDCl3) δ 8.16 (2H, s), 7.34-6.98 (4H, m), 5.67 
(1H, s), 4.68-4.52 (2H, m), 4.49 (2H, s), 3.31-3.06 (4H, dd), 2.43 (2H, m), 2.03 (2H, s), 
1.70 (4H, s), 1.48-1.41 (10H, m), 1.13 (4H, d). Overall yield 42%.  
N-(2-((4-((3-aminopropyl)amino)butyl)amino)-1-(3-hydroxyphenyl)-2-oxoethyl)-6-
guanidinohexanamide (13f): 1H NMR (CDCl3) δ 8.03 (2H, s), 7.71 (1H, s), 7.36-7.26 
(2H, m), 6.83 (1H, s), 5.82 (1H, s), 4.31-4.22 (2H, d), 3.30 (2H, m), 3.09-2.92 (4H, d), 
2.55 (10H, s), 1.41 (14H, s), 1.27 (2H, s). Overall yield 36%.   
N-(2-((4-((3-aminopropyl)amino)butyl)amino)-1-(3,5-dimethoxyphenyl)-2-oxoethyl)-6-




(1H, s), 4.15-3.91 (3H, m), 3.82 (3H, m), 2.91 (4H, m), 1.84 (2H, d), 1.81 (6H, m), 1.49 
(4H, d), 1.05 (6H, t), 0.63 (4H, s). Overall yield 46%. 
N-(2-((4-((3-aminopropyl)amino)butyl)amino)-1-methoxy-2-oxoethyl)-4-
guanidinobutanamide (13h): 1H NMR (CDCl3) δ 8.16 (2H, s), 5.87 (1H, s), 3.32 (3H, s), 
3.13 (2H, s), 1.54 (8H, m), 1.49 (10H, s). Overall yield 33%. 
N-(2-((4-((3-aminopropyl)amino)butyl)amino)-1-(4-bromophenyl)-2-oxoethyl)-4-
guanidinobutanamide (13i): 1H NMR (CDCl3) δ 8.17 (2H, s), 7.77-7.58 (2H, d), 7.40-
7.31 (2H, d), 5.87 (1H, s), 4.63 (2H, s), 3.33 (2H, s), 3.14 (2H, s), 1.55 (4H, s), 1.44 
(10H, s), 1.15 (2H, d). Overall yield 31%.  
N-(2-((4-((3-aminopropyl)amino)phenyl)amino)-1-methoxy-2-oxoethyl)-6-
guanidinohexanamide (13j): 1H NMR (CDCl3) δ 8.28 (2H, s), 7.47 (2H, d), 7.34-7.30 
(2H, d), 5.82 (1H, s), 4.50 (2H, d), 3.49 (2H, m), 2.04 (1H, s), 1.74 (4H, m), 1.51 (4H, d), 
1.26 (4H, s), 0.84 (2H, d). Overall yield 49%. 
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Conclusions and Future Directions 
 
5.1 Conclusions 
Over the last five years, there has been increasing interest in developing inhibitors 
of Hsp70 family members because these chaperones seem to have a role in multiple 
diseases.  This dissertation has focused on advancing our understanding of chaperones 
and their involvement in neurodegenerative diseases by applying multicomponent 
reactions to the synthesis of new chemical probes.   
When I started in 2005, there were few inhibitors that had been identified for 
Hsp70s.1  Taking inspiration from literature accounts, which suggested that 
dihydropyrimidines may modulate  Hsc70 activity, I employed the Biginelli reaction to 
generate a library of compounds in hopes of developing a structure-activity relationship 
(1, Figure 5-1).2  From this work, one interesting observation was that some of these 
compounds modulated tau levels in cell lines. While there appeared to be no discernable 
SAR within the series, these studies led us to screen other scaffolds that might have the 
same phenotype ( but with  increased potency and a discernable SAR profile).  The 
resulting dihydropyridine compound 4a (2, Figure 5-1) increased tau levels in this 
cellular model, so a library of analogs was synthesized.  Dihydropyridines were 
synthesized by employing the Hantzsch reaction and then screened for their ability to 




developed.  Importantly, compound 11g (3, Figure 5-1) was further tested to see if there 
was any dose-dependency to its decrease in tau levels.  It did appear to affect tau levels in 
a dose-dependent manner and appeared to have an IC50 of about ~7 µM, which is a  ~10-
fold  improvement over the dihydropyrimidines.  This work also produced the first 
enantio-selective, four-component Hantszch reaction. Finally, I employed the Ugi 
reaction to synthesize a library of 15-DSG analogs.  Using the Ugi reaction I was able to 
dramatically improve the synthetic route to these types of polyamines (4, Figure 5-1).  
Rather than taking 14 steps to get a 7% yield using methods published in the literature, I 
was able to shorten the number of steps to 7 and improve the yield to the 30-50% range 
for 15-DSG analogs.  Also owing to the fact that the four-component Ugi reaction was 
used, a variety of substitution patterns were created or are anticipated.  I expect that this 
work will allow for the eventual development of a structure-activity relationship.       
While most of my projects have revolved around creating libraries of compounds 
explore structure-activity relationships, the development of an enantioselective Hantzsch 
reaction was a foray into synthetic methodology.  Until the organocatalytic version of this 
reaction was developed, the only way to achieve enantioselection was through the use of 




phosphoric acid catalysts that achieved high enantioselectivity in moderate to high yield 
allowed me to develop an elegant way to synthesize chiral dihydropyridines with 
aromatic substitutions at the C4 position of the heterocycle.     
I have learned a great deal over the last five years.  In 2005, there were only a 
handful of weak Hsp70 inhibitors and little known about “druggable” sites on this family 
of proteins.  The interceding years have provided great opportunities to expand my 
knowledge in synthesis (e.g. by applying a multitude of reactions and even performing 
new methodology studies) - but they have also allowed me to expand my understanding 
of the biology of Hsp70 proteins and molecular chaperones.  It has been rewarding to see 
examples of my Hsp70 inhibitors being applied (by the Gestwicki laboratory, our 
collaborators and others in the field) to help us gain a greater understanding of the 
complicated biology of the Hsp70 family of proteins.          
5.2 Future Directions 
5.2.1 Target Identification for the Dihydropyridine Scaffold 
 While changing the scaffold to a dihydropyridine from a dihydropyrimidine 
allowed for the identification of a new scaffold with more potent activity and a 
preliminary SAR, the binding site for these compounds remains unknown.  Since 
compound 11g (3, Figure 5-1) was the most potent thus far, it might serve as a starting 
point for the generation of biotin-labeled derivatives that could then be used in pull-down 
assays to determine the binding partners of dihydropyridines.  Depending on the target 
protein identified, more rational design of compounds that alter tau stability could be 
done and other scaffolds might be identified through screening.  For this strategy to be 




been published previously.3  The NHS-ester of biotin was synthesized and then 
ethylenediamine was coupled (Scheme 5-1 A).  Once ethylenediamine is coupled to 
biotin it can then be reacted with NHS-acetoacetate under basic conditions (Scheme 5-1 
B).  This β-keto amide can then be used in the Hantzsch reaction to synthesize a 
biotinylated dihydropyridine (Scheme 5-1 C). This route is currently being pursued by 
another graduate student. 
5.2.2 Scaffold Hopping to Identify Other Scaffolds 
 The dihydropyrimidine scaffold has become a starting point in the identification 
of small molecules that bind to members of the Hsp70 protein family.  The binding site 
on DnaK for one of these compound 115-7c was identified in collaboration with Prof. 
Erik Zuiderweg’s laboratory using NMR experiments to identify the putative binding 




provide any compounds that were potent than ~75 µM. I approached this limitation by 
generating dihydropyridines with a related structure.  In the future, these scaffold-
hopping efforts might be combined with in silico screens.  Ideally, one would retain the 
interesting binding site of the dihydropyrimidines, but achieve improved potency. In 
addition, it is also possible that scaffolds that bind to other binding sites could still be 
identified during on-going screening in the Center for Chemical Genomics at the 
University of Michigan’s Life Sciences Institute.  Several members of the laboratory 
have continued to develop new assays and new compound collections continue to become 
available. From my work on the dihydropyrimidines and dihydropyridines (and in 
collaboration with Sussi Wisen, Lyra Chang, Yoshi Miyata and others in the group), a 
“flow chart” of assays and criteria are developing, which should aid these efforts. 
Specifically, we have learned a great deal about how different co-chaperones can be 
employed to modulate the available protein-protein interactions. 
5.2.3 SAR of 15-DSG Analogs 
 The logical next step in the spergualin synthetic project is that more derivatives 
need to be made. From my reading of the literature, I will make a few suggestions:  
While substitutions at the 11 position were not tolerated well in the early SAR studies, 
using the Ugi multicomponent reaction provides new opportunities for substitution (4, 
Figure 5-1).  Further, new derivatives of the starting materials could permit greater 
diversity, such as substitutions to the spermidine tail.  Also only the length of the 
guanidinylated amino acid chain has been probed, while its rigidity and polarity could be 




 In addition to new syntheses, more biochemical tests are needed.  Right now, 
surface plasmon resonance appears most promising. In this experiment,  Hsc70 is bound 
to a chip and the co-chaperone CHIP is flowed over this surface, with the 15-DSG 
analogs competing for the protein-protein interaction.  However, it would be useful to 
have an alternative biochemical assay to measure the affect of the 15-DSG analogs.  
Some [possibilities include: ubiquitin transfer assays and radioactive ATPase assays.5  
These methods would not be ideal for high throughput screening, but they might be 
useful for screening a focused library. This project is obviously at its initial phases. 
5.2.4 The Preparation of Cyclic 15-DSG Derivatives 
 While early indications are that the linear 15-DSG analogs that I have synthesized 
are more stable than spergualin, there are several other ways that would be interesting to 
further increase the stability of these compounds.  One potential way is by forming cyclic 
products.  The first method that I could envision to cyclize the 15-DSG core is to take 
deprotected products and heating them in the microwave with Lawesson’s reagent in 
toluene.  This should produce a five-membered 1,3-thiazole ring (Scheme 5-2).6 The 
alternative method to form a macrocylic ring is to perform the Ugi reaction with 
propargylamine.  The rest of the route remains the same.  After the reductive amination, 




recently published conditions.8  The product is then subjected to an intramolecular 1,3-
cycloaddition using conditions that had been worked out for intramolecular peptide 
cyclization using 1,3-cycloaddition (Scheme 5-3).9, 10  Following deprotection a large 
macrocyclic ring with appendages for the guanidinylated tail, spermidine, and the R 
group replacing the 11 position OH will be present.         
5.2.5 Probe vs. Therapeutic 
 The current state of small molecule modulators of Hsp70 proteins are more likely 
to lead to the development of probes than therapeutic agents.  Specifically, the current 
compounds have modest affinities and lack extensive SAR or toxicology studies.  
However, these compounds may be able to answer important questions about Hsp70 
family members and their roles in biology.  While the ultimate goal might be to develop a 
therapeutic agent, more immediate questions might include:  What is the optimal affinity 




targets for each disease and how do co-chaperones affect them? What is the role of 
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